Self-assembling protein nanostructures displaying paramyxovirus and / or pneumovirus f proteins, and their use
Self-assembling polypeptide nanostructures efficiently display multiple copies of paramyxovirus and pneumovirus F proteins, addressing the slow progress in protein design for biomaterials and enhancing immune response through recombinant production.
Patent Information
- Application Number
- JP2024132065
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2017-04-04
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a slow progress in designing self-assembling proteins for highly functional materials, limiting the development of biomaterials that can efficiently display multiple copies of paramyxovirus and pneumovirus F proteins on their surface.
The development of nanostructures composed of self-assembling polypeptides, where multiple copies of paramyxovirus and pneumovirus F proteins or antigenic fragments are displayed on the external surface through non-covalent interactions, forming symmetrically repeating interfaces that orient the polypeptides into nanostructures like icosahedrons, using recombinant production or chemical synthesis.
The nanostructures effectively display multiple copies of F proteins, inducing an immune response and providing a stable platform for immunogenic compositions, enhancing immune recognition and response against these viruses.
Smart Images

Figure 2024160321000001_ABST
Abstract
Description
[Technical field]
[0001] cross reference This application claims priority to U.S. Provisional Patent Application No. 62 / 481,331, filed April 4, 2017, which is incorporated by reference in its entirety. [Background technology]
[0002] background Molecular self-assembly and co-assembly of proteins into highly ordered symmetric supramolecular complexes is an elegant and powerful means to pattern materials at the atomic scale. In recent years, there has been progress in the development of biomaterials, particularly self-assembled biomaterials composed of nucleic acids. DNA, for example, has been used to create nanoscale shapes and patterns, molecular containers, and three-dimensional macroscopic crystals. Although progress in designing self-assembling proteins has been somewhat slow, the functionality and physical properties of proteins make them attractive as building blocks for developing advanced functional materials. Summary of the Invention [Means for solving the problem]
[0003] Summary of the Invention In one embodiment, a nanostructure comprising: (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, the second polypeptides being different from the first polypeptide; Including, a plurality of first assemblies non-covalently interacting with a plurality of second assemblies to form a nanostructure; Nanostructures are provided, where the nanostructures display multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, on an exterior surface of the nanostructure.
[0004] In one embodiment, (a) a first polypeptide comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs: 1-51; (b) the second polypeptide comprises a polypeptide having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs: 1-51.
[0005] In another embodiment, one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, comprise a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs: 53, 61-68, and 101.
[0006] In various embodiments: (a) the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-31A (SEQ ID NO:51) and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-09B / T33-31B (SEQ ID NO:44); (b) the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-15B (SEQ ID NO:46) and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-15A (SEQ ID NO:45); (c) a first polypeptide has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence of a polypeptide selected from the group consisting of I53-50A (SEQ ID NO:7), I53-50A.1 (SEQ ID NO:29), I53-50A.1NegT2 (SEQ ID NO:30), and I53-50A.1PosT1 (SEQ ID NO:31); or the polypeptide of claim 2 has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of a polypeptide selected from the group consisting of I53-50B (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), and I53-50B.4PosT1 (SEQ ID NO:34); or (d) the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I32-28A (SEQ ID NO:21), and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I32-28B (SEQ ID NO:22).
[0007] In one embodiment, one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, are expressed as fusion proteins with the first polypeptide. In one such embodiment, each of the plurality of first assemblies comprises the same first polypeptide; in another such embodiment, the plurality of first assemblies comprises a total of two or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof. In another embodiment, only a subset of the first polypeptides comprises a fusion protein with the F protein or antigenic fragment thereof. In a further embodiment, each first assembly comprises a homotrimer of the first polypeptide.
[0008] In another embodiment, the fusion protein comprises an amino acid linker disposed between the first polypeptide and a paramyxovirus and / or pneumovirus F protein, or antigenic fragment thereof. In one such embodiment, the fusion protein comprises an amino acid linker disposed between the first polypeptide and a paramyxovirus F protein, or antigenic fragment thereof. In one embodiment, the amino acid linker sequence comprises one or more trimerization domains; in another embodiment, the amino acid linker sequence comprises a Gly-Ser linker.
[0009] In various embodiments, the first polypeptide comprises or consists of a first polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of a polypeptide selected from the group consisting of DS-Cav1-foldon-T33-31A (SEQ ID NO: 69), DS-Cav1-T33-31A (SEQ ID NO: 70), DS-Cav1-foldon-T33-15B (SEQ ID NO: 71), DS-Cav1-T33-15B (SEQ ID NO: 72), DS-Cav1-foldon-I53-50A (SEQ ID NO: 73), DS-Cav1-I53-50A (SEQ ID NO: 74), and DS-Cav1-I32-28A (SEQ ID NO: 75). In other embodiments, (a) each first polypeptide has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1-foldon-T33-31A (SEQ ID NO: 69) or DS-Cav1-T33-31A (SEQ ID NO: 70); (b) each first polypeptide has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1-foldon-T33-15B (SEQ ID NO: 71) or DS-Cav1-T33-15B (SEQ ID NO: 72); (c) each first polypeptide has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1-foldon-I53-50A (SEQ ID NO: 73) or DS-Cav1-I53-50A (SEQ ID NO: 74); each second polypeptide is I53-50B; (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), or I53-50B.4PosT1 (SEQ ID NO:34); or (d) When each first polypeptide has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity along its entire length to the amino acid sequence of DS-Cav1-I32-28A (SEQ ID NO: 75), each second polypeptide has at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity along its entire length to the amino acid sequence of I32-28B.
[0010] In one embodiment, the F protein, or antigenic fragment thereof, of one or more paramyxoviruses and / or pneumoviruses comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1 (SEQ ID NO:53). In one such embodiment, each first polypeptide comprises a fusion polypeptide of a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1 linked via an amino acid linker to a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of SEQ ID NO: 7 (I53-50A). In another embodiment, the amino acid linker comprises a Gly-Ser linker. In further embodiments, each fusion protein comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence selected from the group consisting of SEQ ID NOs: 69-100. In certain embodiments, each fusion protein comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of SEQ ID NO: 76 (F10). In other embodiments, each second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence selected from the group consisting of I53-50B (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), or I53-50B.4PosT1 (SEQ ID NO:34).In certain embodiments, each second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I53-50B.4PosT1 (SEQ ID NO: 34).
[0011] In other aspects, a recombinant expression nucleic acid that expresses a first polypeptide fusion, a recombinant expression vector comprising the recombinant nucleic acid linked to a promoter, and a recombinant host cell comprising the recombinant expression vector are provided.
[0012] Also provided is an immunogenic composition comprising the nanostructure of any embodiment or combination of embodiments disclosed herein, and a pharma- ceutically acceptable carrier. In one embodiment, the immunogenic composition may further comprise an adjuvant.
[0013] In another aspect, a method for generating an immune response to a RSV F protein in a subject or treating or limiting a RSV infection in a subject is provided, comprising administering to a subject in need thereof an effective amount of a nanostructure or immunogenic composition of an embodiment or combination of embodiments disclosed herein to generate an immune response in the subject or treat or prevent a RSV infection.
[0014] Also provided is a process for assembling nanostructures of any embodiment or combination of embodiments disclosed herein, comprising mixing two or more nanostructure components in aqueous conditions to drive spontaneous assembly of the desired nanostructure.
[0015] BRIEF DESCRIPTION OF THE DRAWINGS The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, in which: [Brief description of the drawings]
[0016] [Figure 1] A schematic diagram of the production of antigen-bearing nanostructures by in vitro assembly is shown. The two components or building blocks of a given nanostructure can be expressed and purified separately, and the assembly of the nanostructure can be initiated by mixing the purified components in vitro (a process called in vitro assembly). In some embodiments, the two components of the nanostructure can be expressed in different expression hosts (e.g., human HEK293F cells or bacterial E. coli cells). The figure shows a schematic of the assembly of a 120-subunit nanostructure bearing 20 trimeric antigens (60 antigen subunits) via in vitro assembly of antigen-nanostructure trimer fusion proteins produced in HEK293F cells and nanostructure pentameric proteins produced in E. coli. [Diagram 2] Graph showing detection of secreted DS-Cav1, DS-Cav1-foldon-T33-31A, and DS-Cav1-T33-31A fusion proteins in tissue culture supernatants. ELISA assays were performed on tissue culture supernatants from cells expressing DS-Cav1 (top), DS-Cav-1-foldon-T33-31A / T33-31B (bottom left), and DS-Cav-1-T33-31A / T33-31B (bottom right). Four different monoclonal antibodies that bind RSV F were used to assess the presence of DS-Cav1 or DS-Cav1 fusion proteins in the supernatants. The results confirm the secretion of proteins containing fully folded RSV F antigen. [Diagram 3] Size exclusion chromatography of DS-Cav1-I53-50A. Protein purified from tissue culture supernatant by immobilized metal affinity chromatography was applied to a Superose™ 6 10 / 300GL size exclusion column. Protein eluted as a single monodisperse species. [Figure 4]Size exclusion chromatography of in vitro assembled DS-Cav1-I53-50 nanostructures. Purified DS-Cav1-I53-50A protein and I53-50B.4PT1 protein were mixed in approximately 1:1 molar ratio, incubated overnight at 4°C, and then applied to a Sephacryl S-500 16 / 60 HR size exclusion column. The assembled nanostructures were eluted as a single monodisperse peak at 65mL, while the excess DS-Cav1-I53-50A trimer component was eluted at 90mL. [Diagram 5] Negative staining micrographs and 2D class averages of in vitro assembled DS-Cav1-I53-50 nanostructures. In vitro assembled DS-Cav1-I53-50 nanostructures purified by size exclusion chromatography were imaged by negative staining electron microscopy (top). Averaging over a large number of nanostructures yielded 2D class averages (bottom) that show that the I53-50 portion of the nanostructure is highly ordered and consistent, while the precise 3D position of the displayed antigen varies slightly due to the flexibility of the linker between the DS-Cav1 and I53-50A domains of the DS-Cav1-I53-50A fusion protein. [Figure 6] A series of graphs showing the antigenicity of DS-Cav1-I53-50 nanostructures are shown. Analysis of purified DS-Cav1-I53-50 nanostructures by ELISA using four RSV F-specific monoclonal antibodies (including prefusion-specific antibodies MPE8, D25, and RSD5) (A) showed that DS-Cav1 antigens were correctly folded and maintained in the prefusion state when multivalently displayed on DS-Cav1-I53-50 nanostructures. This finding was confirmed by surface plasmon resonance measurements using multiple RSV F-specific antibodies (B-C), further suggesting that multivalent display of DS-Cav1 results in an avidity effect that reduces the antibody dissociation rate when compared to trimeric DS-Cav1. [Figure 7]1 is a graph showing DS-Cav1 specific serum antibody titers from mice immunized with DS-Cav1-I53-50 nanostructures. Groups of mice were immunized with I53-50 nanostructures lacking the additional antigen trimer DS-Cav1 or with I53-50 nanostructures carrying DS-Cav1 antigens at 33%, 66%, or 100% valency. DS-Cav1 specific serum antibody titers were measured by ELISA against plates coated with DS-Cav1. Serum antibody titers for each mouse were plotted as circles, and the geometric mean within each plotted group was placed as a horizontal line. [Figure 8] 1 is a graph showing serum neutralizing activity induced by immunization with DS-Cav1-I53-50 nanostructures. Groups of mice were immunized with I53-50 nanostructures lacking the additional antigen trimer DS-Cav1 or with I53-50 nanostructures carrying DS-Cav1 antigens at 33%, 66%, or 100% valency. The neutralizing titers for each mouse are plotted as circles, and the geometric mean within each plotted group is plotted as a horizontal line. [Figure 9] Graph showing immunogenicity in the primate immune system induced by immunization with DS-Cav1-foldon I53-50 nanostructures. Rhesus macaques were injected at weeks 0 and 4 with either free DS-Cav1 trimers or DS-Cav1-foldon-I53-50 nanostructures displaying DS-Cav1 at 100% valency. In both cases, the dose of DS-Cav1 antigen was 50 μg and the immunogen was formulated with the MF59-like squalene-based oil-in-water emulsion adjuvant SWE. Sera obtained from animals at weeks 6 and 16 were evaluated for anti-DS-Cav1 antibody titers (A) and RSV-neutralizing antibody titers (B). [Figure 10]Graph showing the physical stability of DS-Cav1 when fused to I53-50A and / or further assembled into icosahedral nanostructures. Samples of trimeric DS-Cav1, trimeric DS-Cav1-foldon-I53-50A, and DS-Cav1-foldon-I53-50 nanostructures containing equal concentrations of DS-Cav1 were divided into four aliquots and incubated at 20, 50, 70, or 80° C. for 1 h. After cooling to room temperature, D25 binding was assayed by surface plasmon resonance (SPR). [Figure 11] Graph showing physical stability of nanostructures. Chemical denaturation with guanidine hydrochloride (GdnHCl) monitored by tryptophan autofluorescence was used as a second antibody-independent technique to assess the physical stability of trimeric DS-Cav1 (A-B), DS-Cav1-foldon-I53-50A (C-D), DS-Cav1-foldon-I53-50 (E-F), I53-50 (G-H), and I53-50A (I-J). The data indicate superior physical stability of the DS-Cav1 antigen when genetically fused to the I53-50A nanostructure component. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] Detailed Description of the Invention All references cited are incorporated herein by reference in their entirety. Unless otherwise stated within this application, the techniques utilized can be found in any of several well-known references, such as: Molecular Cloning: A Laboratory Manual (Sambrook et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press, San Diego, CA), "Guide to Protein Purification" in Methods in Enzymology (MP Deutschcer, ed., (1990) Academic Press, Inc.); PCR Protocols: A Guide to Methods and Applications (Innis et al. 1990. Academic Press, San Diego, CA), Culture of Animal Cells: A Manual of Basic Technique, 2 nd (RIFreshney.1987. Liss, Inc. New York, NY), Gene Transfer and Expression Protocols, pp. 109-128, ed. EJ Murray, The Humana Press Inc., Clifton, NJ), and Ambion 1998 Catalog (Ambion, Austin, TX).
[0018] As used herein, the singular forms "a," "an," and "the" include the plural forms unless the context clearly indicates otherwise. As used herein, "and" is used interchangeably with "or" unless specifically indicated otherwise.
[0019] As used herein, amino acid residues are abbreviated as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).
[0020] As used herein, "about" means ±5% of the cited parameter.
[0021] All embodiments of any aspect of the invention can be used in combination unless the context clearly indicates otherwise.
[0022] Unless the context clearly dictates otherwise, throughout the description and claims, the terms "comprise," "comprising," and the like, are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; in other words, meaning "including, but not limited to." Terms using the singular or plural also include the plural and singular, respectively. Additionally, the terms "herein," "above," "below," and words of similar import, when used in this application, shall refer to this application as a whole and not to particular portions of this application.
[0023] The description of the embodiments of the present disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the present disclosure are described herein for illustrative purposes only, various equivalent modifications are possible within the scope of the present disclosure, as those skilled in the art will recognize.
[0024] In a first aspect, the present disclosure provides a nanostructure comprising: (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, the second polypeptides being different from the first polypeptide; Including, a plurality of first assemblies non-covalently interacting with a plurality of second assemblies to form a nanostructure; Nanostructures are provided, where the nanostructures display multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, on an exterior surface of the nanostructure.
[0025] Disclosed herein are self-assembling polypeptide nanostructures that display a multivalent paramyxovirus and / or pneumovirus F protein on the outer surface of the nanostructure. Multiple copies of a pair of first and second polypeptides can self-assemble to form a nanostructure, such as an icosahedral nanostructure. The nanostructure comprises a symmetrically repeated non-natural non-covalent polypeptide-polypeptide interface that orients the first assembly and the second assembly into the nanostructure, such as a nanostructure having icosahedral symmetry.
[0026] The nanostructures of the present invention are synthetic in that they do not occur in nature. The first and second polypeptides are non-naturally occurring proteins that can be produced by any suitable means, including recombinant production or chemical synthesis. Each member of the first polypeptides of the plurality is identical to each other (however, when the first polypeptide exists as a fusion polypeptide with one or more paramyxovirus and / or pneumovirus F proteins or antigenic fragments thereof, the F protein or antigenic fragments thereof may differ from one first polypeptide to another), and each member of the second polypeptides of the plurality is identical to each other. The first protein and the second protein are different. There is no specific requirement of the primary amino acid sequence for the first and second polypeptides. US Patent Application Publication No. 20160122392 and PCT Application Publication No. WO2014 / 124301 describe a method of designing a synthetic nanostructure, where the nanostructure does not depend on the specific primary amino acid sequence of the first and second polypeptides.
[0027] A plurality (2, 3, 4, 5, 6, or more) of first polypeptides self-assemble to form a first assembly, and a plurality (2, 3, 4, 5, 6, or more) of second polypeptides self-assemble to form a second assembly, and then a plurality of these first and second assemblies non-covalently self-assemble through the engineered interface to produce the nanostructure.
[0028] The number of first polypeptides in the first assembly may be the same or different from the number of second polypeptides in the second assembly. In one exemplary embodiment, the first assembly comprises a trimer of the first polypeptide, and the second assembly comprises a dimer of the second polypeptide. In a further exemplary embodiment, the first assembly comprises a trimer of the first polypeptide, and the second assembly comprises a trimer of the second polypeptide. In a further exemplary embodiment, the first assembly comprises a trimer of the first polypeptide, and the second assembly comprises a pentamer of the second polypeptide.
[0029] The first and second polypeptides can be of any length suitable for a given purpose of the resulting nanostructure. In one embodiment, the first and second polypeptides are typically 30-250 amino acids in length; the lengths of the first and second polypeptides can be the same or different. In various further embodiments, the first and second polypeptides are 30-225, 30-200, 30-175, 50-250, 50-225, 50-200, 50-175, 75-250, 75-225, 75-200, 75-175, 100-250, 100-225, 100-200, 100-175, 125-250, 125-225, 125-200, 125-175, 150-250, 150-225, 150-200, and 150-175 amino acids in length.
[0030] The isolated polypeptides of SEQ ID NOs: 1-51 were designed to be capable of self-assembly in pairs to form nanostructures, such as icosahedral nanostructures. The design was of appropriate interface residues for each member of the polypeptide pair that can assemble to form a nanostructure. The nanostructures so formed comprise symmetrically repeated non-natural non-covalent polypeptide-polypeptide interfaces that orient the first and second assemblies into a nanostructure, such as a nanostructure having icosahedral symmetry. Thus, in one embodiment, the first and second polypeptides are selected from the group of SEQ ID NOs: 1-51. In each case, the N-terminal methionine residue is optional.
[0031] [Table 1] TIFF2024160321000003.tif218160TIFF2024160321000004.tif219160I53-40A genus (SEQ ID NO: 35) (M)TKKVGIVDTTFARVDMASAAILTLKMESPNIKIIRKTVPGIKDLPVACKKLLEEEGCDIVMALGMPGK(A / K)EKDKVCAHEASLGLMLAQLMTNKHIIEVFVHEDEAKDDAELKILAARRAIEHALNVYYLLFKPEYLTRMAGKGLRQGFEDAGPARE (Genus I53-40B (SEQ ID NO: 36)) (M)(S / D)(T / D)INNQLK(A / R)LKVIPVIAIDNAEDIIPLGKVLAENGLPAAEITFRSSAAVKAIMLLRSAQPEMLIGAGTILNGVQALAAKEAGA(T / D)FVVSPGFNPNTVRACQIIGIDIVPGVNNPSTVE(A / Q)ALEMGLTTLKFFPAEASGGISMVKSLVGPYGDIRLMPTGGITP(S / D)NIDNYLAIPQVLACGGTWMVDKKLV(T / R)NGEWDEIARLTREIVEQVNP (Genus I53-47A (SEQ ID NO: 37)) (M)PIFTLNTNIKA(T / D)DVPSDFLSLTSRLVGLILS(K / E)PGSYVAVHINTDQQLSFGGSTNPAAFGTLMSIGGIEP(S / D)KN(R / E)DHSAVLFDHLNAMLGIPKNRMYIHFV(N / D)L(N / D)GDDVGWNGTTF (Genus I53-47B (SEQ ID NO: 38)) (M)NQHSHKD(Y / H)ETVRIAVVRARWHADIVDACVEAFEIAMAAIGGDRFAVDVFDVPGAYEIPLHARTLAETGRYGAVLGTAFVV(N / D)GGIY(R / D)HEFVASAVIDGMMNVQL(S / D)TGVPVLSAVLTPH(R / E)Y(R / E)DS(A / D)E(H / D)H(R / E)FFAAHFAVKGVEAARACIEIL(A / N)AREKIAA (Genus I53-50A (SEQ ID NO: 39)) (M)KMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGH(T / D)IL KLFPGEVVGP(Q / E)FV(K / E)AMKGPFPNVKFVPTGGV(N / D)LD(N / D)VC(E / K)WF(K / D)AGVLAVGVG(S / K / D)ALV(K / E)G(T / D / K)PDEVRE(K / D)AK(A / E / K)FV(E / K)(K / E)IRGCTE I53-50B 40-inch range) (M)NQHSHKD(Y / H)ETVRIAVVRARWHAEIVDACVSAFEAAM(A / R)DIGGDRFAVDVFDVPGAYEIPLHARTLAETGRYGAVLGTAFVV(N / D)GGIY(R / D). )HEFVASAVI(D / N)GMMNVQL(S / D / N)TGVPVLSAVLTPH(R / E / N)Y(R / D / E)(D / K)S(D / K)A(H / D)TLLFLALFAVKGMEAARACVEILAAREKIAA T32-28A (Highway 41) (M)GEVPIGDPKELNGMEIAAVYLQPIEMEPRGIDLAASLADIHLEADIHALKNNPNGFPEGFWMPYLTIAYALANADTGAIKTGTLMPMVADDGPHYGANIAMEKDKKGGFGVGTYALTFLISNPEKQGFGRHVDEETGVGKWFEPFVVTYFFKYTGTPK T32-28B (Highway 42) (M)SQAIGILELTSIAKGMELGDAMLKSANVDLLVSKTISPGKFLLMLGGDIGAIQQAIETGTSQAGEMLVDSLVLANIHPSVLPAISGLNSV DKRQAVGIVETWSVAACISAADLAVKGSNVTLVRVHMAFGIGGKCYMVVAGDVLDVAAAVATASLAAGAKGLLVYASIIPRPHEAMWRQMVEG T33-09A (SEQ ID NO: 43) (M)EEVVLITVPSALVAVKIAHALVEERLAACVNIVPGLTSIYRWQGSVVSDHELLLLVKTTTHAFPKLKERVKALHPYTVPEIVALPIAEGNREYLDWLRENTG T33-09B (SEQ ID NO: 44) (M)VRGIRGAITVEEDTPAAILAATIELLLKMLEANGIQSYEELAAVIFTVTEDLTSAFPAEAARLIGMHRVPLLSAREVPVPGSLPRVIRVLALWNTDTPQDRVRHVYLNEAVRLRPDLESAQ T33-15A (SEQ ID NO: 45) (M)SKAKIGIVTVSDRASAGITADISGKAIILALNLYLTSEWEPIYQVIPDEQDVIETTLIKMADEQDCCLIVTTGGTGPAKRDVTPEATEAVCDRMMPGFGELMRAESLKEVPTAILSRQTAGLRGDSLIVNLPGDPASISDCLLAVFPAIPYCIDLMEGPYLECNEAMIKPFRPKAK T33-15B (SEQ ID NO: 46) (M)VRGIRGAITVNSDTPTSIIIATILLLEKMLEANGIQSYEELAAVIFTVTEDLTSAFPAEAARQIGMHRVPLLSAREVPVPGSLPRVIRVLALWNTDTPQDRVRHVYLSEAVRLRPDLESAQ T33-21A (SEQ ID NO: 47) (M)RITTKVGDKGSTRLFGGEEVWKDSPIIEANGTLDELTSFIGEAKHYVDEEMKGILEEIQNDIYKIMGEIGSKGKIEGISEERIAWLLKLILRYMEMVNLKSFVLPGGTLESAKLDVCRTIARRALRKVLTVTREFGIGAEAAAYLLALSDLLFLLARVIEIEKNKLKEVRS T33-21B (SEQ ID NO: 48) (M)PHLVIEATANLRLETSPGELLEQANKALFASGQFGEADIKSRFVTLEAYRQGTAAVERAYLHACLSILDGRDIATRTLLGASLCAVLAEAVAGGGEEGVQVSVEVREMERLSYAKRVVARQR T33-28A (SEQ ID NO: 49) (M)ESVNTSFLSPSLVTIRDFDNGQFAVLRIGRTGFPADKGDIDLCLDKMIGVRAAQIFLGDDTEDGFKGPHIRIRCVDIDDKHTYNAMVYVDLIVGTGASEVERETAEEEAKLALRVALQVDIADEHSCVTQFEMKLREELLSSDSFHPDKDEYYKDFL T33-28B (SEQ ID NO:50) (M)PVIQTFVSTPLDHHKRLLLAIIYRIVTRVVLGKPEDLVMMTFHDSTPMHFFGSTDPVACVRVEALGGYGPSEPEKVTSIVTAAITAVCGIVADRIFVLYFSPLHCGWNGTNF T33-31A (SEQ ID NO:51) (M)EEVVLITVPSALVAVKIAHALVEERLAACVNIVPGLTSIYREEGSVVSDHELLLLVKTTTDAFPKLKERVKELHPYEVPEIVALPIAEGNREYLDWLRENTG
[0032] Table 1 provides the amino acid sequences of the first and second polypeptides; the right column of Table 1 identifies the number of residues in each exemplary polypeptide that were identified to be present at the interface of the resulting assembled nanostructure (i.e., the "identified interface residues"). As will be seen, the interface residue numbers of the exemplary polypeptides of SEQ ID NOs: 1-34 range from 4 to 13. In various embodiments, the first and second polypeptides comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over its length to the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs: 1-34, and is identical at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 identified interface positions (depending on the interface residue number for a given polypeptide). In other embodiments, the first and second polypeptides comprise an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical over their length and identical at at least 20%, 25%, 33%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, or 100% of the identified interface positions to the amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs:1-51.
[0033] As with proteins in general, it is expected that polypeptides will tolerate some variation in the designed sequence (especially when such variation includes conservative amino acid substitutions) without disrupting the subsequent assembly into nanostructures. As used herein, "conservative amino acid substitution" means that: hydrophobic amino acids (Ala, Cys, Gly, Pro, Met, See, Sme, Val, Ile, Leu) can only be replaced with other hydrophobic amino acids; hydrophobic amino acids with bulky side chains (Phe, Tyr, Trp) can only be replaced with other hydrophobic amino acids with bulky side chains; amino acids with positively charged side chains (Arg, His, Lys) can only be replaced with other amino acids with positively charged side chains; amino acids with negatively charged side chains (Asp, Glu) can only be replaced with other amino acids with negatively charged side chains; amino acids with polar uncharged side chains (Ser, Thr, Asn, Gln) can only be replaced with other amino acids with polar uncharged side chains.
[0034] Table 2 lists the surface amino acid residue numbers for each exemplary polypeptide of the invention designated SEQ ID NOs: 1-34. Thus, in various embodiments, one or more (at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more) of these surface residues in a polypeptide of the invention can be modified. Residues in brackets are optional.
[0035] [Table 2] TIFF2024160321000006.tif220160TIFF2024160321000007.tif213160TIFF2024160321 000008.tif216160TIFF2024160321000009.tif218160TIFF2024160321000010.tif16160
[0036] In various embodiments of the nanostructures of the invention, the first and second polypeptides are the following pairs, or modified versions thereof (i.e., permissible modifications as disclosed for the polypeptides of the invention: isolated polypeptides comprising an amino acid sequence that is at least 75% 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over its length and / or at least one identified interface position to the amino acid sequence set forth in the SEQ ID NO:): SEQ ID NO:1 and SEQ ID NO:2 (I53-34A and I53-34B); SEQ ID NO:3 and SEQ ID NO:4 (I53-40A and I53-40B); SEQ ID NO:3 and SEQ ID NO:24 (I53-40A and I53-40B.1); SEQ ID NO:23 and SEQ ID NO:4 (I53-40A.1 and I53-40B); SEQ ID NO:35 and SEQ ID NO:36 (genera I53-40A and I53-40B); SEQ ID NO:5 and SEQ ID NO:6 (I53-47A and I53-47B); SEQ ID NO:5 and SEQ ID NO:27 (I53-47A and I53-47B.1); SEQ ID NO:5 and SEQ ID NO:28 (I53-47A and I53-47B.1NegT2); SEQ ID NO:25 and SEQ ID NO:6 (I53-47A.1 and I53-47B); SEQ ID NO:25 and SEQ ID NO:27 (I53-47A.1 and I53-47B.1); SEQ ID NO:25 and SEQ ID NO:28 (I53-47A.1 and I53-47B.1NegT2); SEQ ID NO:26 and SEQ ID NO:6 (I53-47A.1NegT2 and I53-47B); SEQ ID NO:26 and SEQ ID NO:27 (I53-47A.1NegT2 and I53-47B.1); SEQ ID NO:26 and SEQ ID NO:28 (I53-47A.1NegT2 and I53-47B.1NegT2); SEQ ID NO:37 and SEQ ID NO:38 (genera I53-47A and I53-47B); SEQ ID NO:7 and SEQ ID NO:8 (I53-50A and I53-50B); SEQ ID NO:7 and SEQ ID NO:32 (I53-50A and I53-50B.1); SEQ ID NO:7 and SEQ ID NO:33 (I53-50A and I53-50B.1NegT2); SEQ ID NO:7 and SEQ ID NO:34 (I53-50A and I53-50B.4PosT1); SEQ ID NO:29 and SEQ ID NO:8 (I53-50A.1 and I53-50B); SEQ ID NO:29 and SEQ ID NO:32 (I53-50A.1 and I53-50B.1); SEQ ID NO:29 and SEQ ID NO:33 (I53-50A.1 and I53-50B.1NegT2); SEQ ID NO:29 and SEQ ID NO:34 (I53-50A.1 and I53-50B.4PosT1); SEQ ID NO:30 and SEQ ID NO:8 (I53-50A.1NegT2 and I53-50B); SEQ ID NO:30 and SEQ ID NO:32 (I53-50A.1NegT2 and I53-50B.1); SEQ ID NO:30 and SEQ ID NO:33 (I53-50A.1NegT2 and I53-50B.1NegT2); SEQ ID NO:30 and SEQ ID NO:34 (I53-50A.1NegT2 and I53-50B.4PosT1); SEQ ID NO:31 and SEQ ID NO:8 (I53-50A.1PosT1 and I53-50B); SEQ ID NO:31 and SEQ ID NO:32 (I53-50A.1PosT1 and I53-50B.1); SEQ ID NO:31 and SEQ ID NO:33 (I53-50A.1PosT1 and I53-50B.1NegT2); SEQ ID NO:31 and SEQ ID NO:34 (I53-50A.1PosT1 and I53-50B.4PosT1); SEQ ID NO:39 and SEQ ID NO:40 (genera I53-50A and I53-50B); SEQ ID NO:9 and SEQ ID NO:10 (I53-51A and I53-51B); SEQ ID NO:11 and SEQ ID NO:12 (I52-03A and I52-03B); SEQ ID NO:13 and SEQ ID NO:14 (I52-32A and I52-32B); SEQ ID NO:15 and SEQ ID NO:16 (I52-33A and I52-33B) SEQ ID NO:17 and SEQ ID NO:18 (I32-06A and I32-06B); SEQ ID NO:19 and SEQ ID NO:20 (I32-19A and I32-19B); SEQ ID NO:21 and SEQ ID NO:22 (I32-28A and I32-28B); SEQ ID NO:23 and SEQ ID NO:24 (I53-40A.1 and I53-40B.1); SEQ ID NO:41 and SEQ ID NO:42 (T32-28A and T32-28B); SEQ ID NO:43 and SEQ ID NO:44 (T33-09A and T33-09B); SEQ ID NO:45 and SEQ ID NO:46 (T33-15A and T33-15B); SEQ ID NO:47 and SEQ ID NO:48 (T33-21A and T33-21B); SEQ ID NO:49 and SEQ ID NO:50 (T33-28A and T32-28B); and Includes polypeptides having an amino acid sequence selected from SEQ ID NO:51 and SEQ ID NO:44 (T33-31A and T33-09B (also referred to as T33-31B)).
[0037] In one embodiment, one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, are expressed as a fusion protein with the first and / or second polypeptide. In these embodiments, one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, are preferably present at the N-terminus of the fusion protein, which configuration can always facilitate the presentation of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, on the outer surface of the nanostructure. This preferred presence of paramyxovirus and / or pneumovirus F proteins at the N-terminus of the fusion protein is due to the presence of the C-terminus of the paramyxovirus and / or pneumovirus F proteins at one end ("bottom") of the F protein trimer; with the genetic fusion at this point, the majority of the F protein structure will be displayed and accessible on the outer surface of the nanostructure. In a further embodiment, the nanostructure comprises at least two domains - a paramyxovirus and / or pneumovirus F protein, or antigenic fragment thereof, and one or more copies of a fusion protein comprising a trimer assembly domain (i.e., each first assembly is a homotrimer of a first polypeptide) - and one or more copies of a second oligomer block (i.e., each second assembly is an oligomer of two or more copies of a second polypeptide). In another embodiment, the first or second polypeptide can be modified such that one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, are covalently linked to the first and / or second polypeptide. In one non-limiting example, the first and / or second polypeptide can be modified, such as by introducing various cysteine residues at defined positions to facilitate linkage of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof.
[0038] In other embodiments, one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, are attached to the first or second polypeptide by any suitable technique, including but not limited to, covalent chemical crosslinking (by any suitable crosslinking technique) and non-covalent bonds (including artificial electrostatic interactions).
[0039] Trimer Assembly Domain In one embodiment of the trimeric assembly comprising a trimeric paramyxovirus and / or pneumovirus F protein, or antigenic fragment thereof, the paramyxovirus and / or pneumovirus F protein, or antigenic fragment thereof, is genetically fused to a first polypeptide, thereby self-assembling into a trimeric assembly. The trimeric assembly comprises a protein-protein interface that induces three copies of the first polypeptide to self-associate to form a trimeric base unit. Each copy of the first polypeptide further comprises a surface-exposed interface that interacts with a complementary surface-exposed interface on the second assembly domain. As described in King et al. (Nature 510,103-108,2014), Bale et al. (Science 353,389-394,2016), and patent publications WO2014124301A1 and US20160122392A1, a complementary protein-protein interface between the trimer assembly domain and the second assembly domain drives the assembly of multiple copies of the trimer assembly domain and the second assembly domain into a target nanostructure. In some embodiments, each copy of the trimer assembly domain of the nanostructure carries a paramyxovirus and / or pneumovirus F protein, or an antigenic fragment thereof, as a genetic fusion; these nanostructures display the F protein in full valency. In other embodiments, the nanostructures of the invention comprise one or more copies of a trimer assembly domain carrying a paramyxovirus and / or pneumovirus F protein, or an antigenic fragment thereof, as a genetic fusion and one or more trimer assembly domains that do not carry an F protein as a genetic fusion; these nanostructures display the F protein in partial valency. The trimer assembly domain can be any polypeptide sequence that forms trimers and interacts with a second assembly domain to drive assembly into a target nanostructure.
[0040] In one particular embodiment, the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-31A (SEQ ID NO:51), and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-09B / T33-31B (SEQ ID NO:44) (residues in brackets are optional). T33-31A (SEQ ID NO:51) (M)EEVVLITVPSALVAVKIAHALVEERLAACVNIVPGLTSIYREEGSVVSDHELLLLVKTTTDAFPKLKERVKELHPYEVPEIVALPIAEGNREYLDWLRENTG >T33-31B (SEQ ID NO: 44) (M)VRGIRGAITVEEDTPAAILAATIELLLKMLEANGIQSYEELAAVIFTVTEDLTSAFPAEAARLIGMHRVPLLSAREVPVPGSLPRVIRVLALWNTDTPQDRVRHVYLNEAVRLRPDLESAQ
[0041] In another specific embodiment, the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-15A (SEQ ID NO:45) and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-15B (SEQ ID NO:46).
[0042] In various further specific embodiments, the first polypeptide is a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of a polypeptide selected from the group consisting of I53-50A (SEQ ID NO:7), I53-50A.1 (SEQ ID NO:29), I53-50A.1NegT2 (SEQ ID NO:30), and I53-50A.1PosT1 (SEQ ID NO:31). and a second polypeptide comprising a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence of a polypeptide selected from the group consisting of I53-50B (SEQ ID NO:8), I53-50B.1 (SEQ ID NO:32), I53-50B.1NegT2 (SEQ ID NO:33), and I53-50B.4PosT1 (SEQ ID NO:34).
[0043] In another specific embodiment, the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I32-28A (SEQ ID NO:21) and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I32-28B (SEQ ID NO:22).
[0044] The nanostructures of the present invention display multiple (i.e., 2, 3, or more) copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, on the exterior surface of the nanostructure. Exemplary paramyxovirus and / or pneumovirus include, but are not limited to, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) (CL Afonso et al., Taxonomy of the order Mononegavirales: update 2016. Arch. Virol. 161, 2351-2360 (2016)).
[0045] As used herein, "on the outer surface of the nanostructure" means that the antigenic portion of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, must be accessible for binding by a B cell receptor, antibody, or antibody fragment, and must not be buried within the nanostructure.
[0046] The one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, may comprise any suitable native F protein, post-fusion antigen, or pre-fusion (preF) antigen, or mutants thereof, capable of inducing an immune response that generates antibodies that bind to the paramyxovirus and / or pneumovirus F protein. The nanostructure may display more than one F protein; thus, in some embodiments, the one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, comprise one, two, three, four, or more F proteins, or antigenic fragments thereof. In one embodiment, the one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, may be as defined in US Patent Application Publication No. 2016 / 0046675A1. In some embodiments, as disclosed in U.S. Patent Application Publication No. 2016 / 0046675, the F protein of one or more paramyxoviruses and / or pneumoviruses, or antigenic fragments thereof, is selected from the group consisting of SEQ ID NOs: 1-350, 370-382, 389-693, 698-1026, 1429-1442, 1456-1468, and 1474-1478. In other embodiments, one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, are provided by the methods described in WO2012158613, US20160102123, US20140141037, WO2014079842, WO2014160463, US20140271699, EP2970393, WO2014174018, US20140271699, US20160176932, US20160122398, WO2017040387, WO2017109629, WO2017172890, WO2017207477, Krarup et al. (2015) Nature Communications 6:8143, and WO2017207480.
[0047] In certain embodiments, the F protein, or antigenic fragment thereof, of one or more paramyxoviruses and / or pneumoviruses comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1 shown below (note that the residues in brackets are optional; the N-terminal residues in brackets are cleaved from the protein during secretion - the mature N-terminus begins with QNITEEF··· (SEQ ID NO:52)). DS-Cav1 comprises a pre-fusion stabilized form of the fusion (F) glycoprotein, which induces an improved protective response against respiratory syncytial virus (RSV) in mice and macaques compared to post-fusion RSV F (McLellan et al. (2013) Science 342:592-8). DS-Cav1 (SEQ ID NO:53): (MELLILKANAITTILTAVTSFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNV TLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSE LLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVD IFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)
[0048] In other embodiments, the F protein can comprise a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to a polypeptide selected from the following: RSV-F sc9-10 DS-Cav1 A149C Y458C (SEQ ID NO: 61) (MELLILKANAITTILTAVTSFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATGSGSAICSGVAVCK VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSN NVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKI MTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL) sc9-10 DS-Cav1 A149C Y458C S46G K465Q S215P E92D (SEQ ID NO: 62) (MELLILKANAITTILTAVTSFCFASG)QNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCK VLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSN NVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKI MTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)
[0049] SEQ ID NOs: 61-62 show second generation stabilized DS-Cav1 immunogens; it should be noted that mutations to DS-Cav1 are described and that the present disclosure contemplates the use of DS-Cav1 variants that differ by a single described amino acid substitution, or by two or more described amino acid substitutions in SEQ ID NOs: 61 or 62 above. In other embodiments, the F protein can include one or more of the following, each of which may further include one, two, or more of the described amino acid substitutions in SEQ ID NOs: 61 or 62 above: RSV F SC-DM (N67I, S215P) (SEQ ID NO: 63) (MELLILKANAITTILTAVTSFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKKIKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNQARGSGSGRSLGFLLGVGSAIASG VAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQ QSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIV SCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELLSAIGGYIPEAPRDGQAYVRKDGEWVLLSTFL) SC-TM (N67I, S215P, and E487Q) (SEQ ID NO: 64) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKKIKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNQARGSGSGRSLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDQFDASISQVNEKINQSLAFIR(KSDELLSAIGGYIPEAPRDGQAYVRKDGEWVLLSTFL) HMPV F protein, CAN97 - 83(A2) strain (SEQ ID NO: 65) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTAG VAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLM LENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCKVSTGR HPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTG HMPVF (SEQ ID NO: 66) with A113C, A339C, T160F, I177L (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTAG VAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLM LENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPCKVSTGR HPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTG HMPV F (SEQ ID NO:67) with A113C, A120C, A339C, T160F, I177L, and Q426C (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTCG VAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLM LENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPCKVSTGR HPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYCLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTG HMPV F>AAK62968.2 fusion protein [human metapneumovirus] (SEQ ID NO: 101) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIADLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGFLIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNTG 115-BV(A185P) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRRRRFVLGAIALGVATAAAVTAGVAIAKTIRLESEV TAIKNALKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMV QLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAAGINVAEQSKECNINISTTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGC SYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNT(SGRENLYFQGGGGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGGIEGRHHHHHH)
[0050] In other embodiments, the F protein, or antigenic fragment thereof, of one or more paramyxoviruses and / or pneumoviruses may include a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to a RSV F protein or variant thereof selected from the group consisting of SEQ ID NOs: 53 and 61-64, wherein the polypeptide includes one or more of the following residues: 67I, 149C, 458C, 46G, 465Q, 215P, 92D, and 487Q.
[0051] In other embodiments, the one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, can comprise a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an MPV F protein or variant thereof selected from the group consisting of SEQ ID NOs: 65-68 and 101, wherein the polypeptide comprises one or more of the following residues: 113C, 120C, 339C, 160F, 177L, 185P, and 426C.
[0052] Linker and geometric requirements between the F protein and the trimer assembly domain In the nanostructures of the present invention, the F protein and the trimer assembly domain can be genetically fused such that they are both present in a single polypeptide. Preferably, the link between the F protein and the trimer assembly domain allows the F protein or its antigen fragment to be displayed on the outer surface of the nanostructures of the present invention. As such, the connection point of the trimer assembly domain should be present on the outer surface of the nanostructure formed by the trimer assembly domain and the second assembly domain in the absence of any F protein. As will be understood by those skilled in the art, a wide variety of polypeptide sequences can be used to link the F protein, or its antigen fragment, and the trimer assembly domain of a paramyxovirus and / or pneumovirus. These polypeptide sequences are referred to as linkers. Any suitable linker can be used; there is no requirement for the amino acid sequence to function as a suitable linker. There is no requirement for the linker to impose a rigid relative orientation of the F protein or its antigen fragment to the trimer assembly domain beyond the requirement to allow the F protein or its antigen fragment to be displayed on the outer surface of the nanostructures of the present invention. In some embodiments, the linker contains an additional trimerization domain (eg, the foldon domain of T4 fibritin) that helps stabilize the F protein in the trimeric form.
[0053] T4 fibritin foldon domain (optional in linker region) (SEQ ID NO:54) GYIPEAPRDGQAYVRKDGEWVLLSTFL In other embodiments, the linker can include a Gly-Ser linker of any suitable length (i.e., a linker consisting of glycine and serine residues). In various embodiments, the Gly-Ser linker can be 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more amino acids long. In various embodiments, the Gly-Ser linker can include or consist of the amino acid sequence of GSGGSGSGSGGSGSG (SEQ ID NO:55), GGSGGSGS (SEQ ID NO:56), or GSGGSGSG (SEQ ID NO:57).
[0054] In further embodiments, the linker can include a helical extension domain that can function to extend the N-terminal helix of the first polypeptide when expressed as a fusion polypeptide with one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, such that the linker is located on the outer surface of the nanostructure surface. The helical extension can be present or absent in combination with other linker components described herein. The helical extension can be of any suitable length (i.e., 7, 8, 9, 10, 11, 12 or more amino acids) and can include any suitable primary amino acid sequence. In one embodiment, the helical extension can include or consist of the amino acid sequence EKAAKAEEAAR (SEQ ID NO:58).
[0055] Thus, in various non-limiting embodiments in which the F protein is present as a fusion protein with the first polypeptide and a linker is used, the F protein-linker sequence may include the following (exemplified in these non-limiting embodiments by DS-Cav1 as the F protein): The residues in brackets are optional, and the amino acid sequence MELLILKANAITTILTAVTFCFASG (SEQ ID NO:59) represents the N-terminal DS-Cav1 signal peptide that is cleaved during processing. DS-Cav1-foldon (SEQ ID NO: 60): (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKR KRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITND QKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSS SVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLGYIPEAPRDGQAYVRKDGEWVLLSTFL
[0056] In various further embodiments, the first polypeptide comprises or consists of a fusion polypeptide of the first polypeptide fused to an F protein, the fusion protein having a sequence selected from the following (optional residues in brackets): DS-Cav1-foldon-T33-31A (SEQ ID NO: 69) (MELLILKANVIATILTAVTFCFASS)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHL EGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLC TTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFP SDEFDASISQVNEKINQSLAFIRKSDELLGYIPEAPRDGQAYVRKDGEWVLLSTFLGGSMEEVVLITVPSALVKIAHALVEERLAACVNIVPGLTSIYREEGSVVSDHELLLLVKTTTDAFPKLKERVKELHPYEVPEIVALPIAEGNREYLDWLRENTG DS-Cav1-T33-31A (SEQ ID NO: 70) (MELLILKANVIATILTAVTFCFASS)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLGGSMEEVVLITVPSALVAVKIAHALVEERLAACVNIVPGLTSIYREEGSVVSDHELLLLVKTTTDAFPKLKERVKELHPYEVPEIVALPIAEGNREYLDWLRENTG DS-Cav1-foldon-T33-15B (SEQ ID NO: 71) (MELLILKANVIATILTAVTFCFASS)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLGYIPEAPRDGQAYVRKDGEWVLLSTFLGGSMVRGIRGAITVNSDTPTSIIIATILLLEKMLEANGIQSYEELAAVIFTVTEDLTSAFPAEAARQIGMHRVPLLSAREVPVPGSLPRVIRVLALWNTDTPQDRVRHVYLSEAVRLRPDLESAQ DS-Cav1-T33-15B (SEQ ID NO: 72) (MELLILKANVIATILTAVTFCFASS)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLGGSMVRGIRGAITVNSDTPTSIIIATILLLEKMLEANGIQSYEELAAVIFTVTEDLTSAFPAEAARQIGMHRVPLLSAREVPVPGSLPRVIRVLALWNTDTPQDRVRHVYLSEAVRLRPDLESAQ DS-Cav1-foldon-I53-50A(SEQ ID NO: 73) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-I53-50A (SEQ ID NO: 74) (MELLILKANVIATILTAVTFCFASS)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-I32-28A (SEQ ID NO: 75) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNRRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCVLHLEGEVNKI KSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRT DRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFDYPLVFPSDEFDASISQVNEKINQSLAFI RKSDELLGGSGGSGSDDARIAAIGDVDELNSQIGVLLAEPLPDDVRAALSAIQHDLFDLGGELCIPGHAAITEDHLLRLALWLVHYNGQLPPLEEFILPGGARGAALAHVCRTVCRRAERSIKALGASEPLNIAPAAYVNLLSDLLFVLARVLNRAAGGADVLWDRTRAH DS-Cav1-8GS-HelExt-I53-50A(F10) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSL SNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNR VFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKKTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFDYPLVFPSDEFDASISQVNEKINQSLAFIRGSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVE EAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFCAGVLAVVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-foldon-15GS-HelExt-I53-50A(F14) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGGSGSGSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV F wt_CAN97-83 strain - I53-50A (SEQ ID NO: 78) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGFIIVIILIAVLGSSMILVSIFIIIKKTKKPTGAPPELSGVTNNGFIPHSGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV F A113C_A339C_T160F_I177L-I53-50A (SEQ ID NO: 79) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNK NKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPC KVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGGSGSHHHHHHHGGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEE AIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV F A113C_A339C_T160F_I177L_A120C, Q426C mutation-I53-50A (SEQ ID NO: 80) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTCGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYCLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE sc-DS2-I53-50A (SEQ ID NO: 81) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATGSGSCIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE tc-DS2-I53-50A (SEQ ID NO: 82) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNRRARRELPRFMNYTLNNAKKTNVTLSKRKRRFLGFLLGVGSCIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNG VSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTM NSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGKSLYVKGEPIINFDYPLVFPSDEFDASISQVNEKINQSLAFIRGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRAN SVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFCAGVLAVVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-12GS-HelExt-I53-50A(F11) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLS NGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVF CDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFDYPLVFPSDEFDASISQVNEKINQSLAFIRGSGGSGSGSGGSEKAAKAEEAARKMEELFKKHKIVAVLRANSV EEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFCAGVLAVVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-16GS-HelExt-I53-50A(F12) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGSGGSGSGSGGSGSGGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-foldon-10GS-HelExt-I53-50A(F13(SEQ ID NO: 85) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYNAVTELQLLMQSTPATNRRARRELPRFMNYTLNNAKKTNVTLSKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVL TFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLEITREFSVNAGVTTPVSTYMLTNSELLSLINMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSE VNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGGSGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGFPPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE DS-Cav1-foldon-20GS-HelExt-I53-50A(F15) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGGSGSGSGGSGSGGSSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE sc9-10 DS-Cav1 A149C Y458C-foldon-I53-50A embodiment (SEQ ID NO: 87) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE sc9-10 DS-Cav1 A149C Y458C-I53-50A-F10 Embodiment (SEQ ID NO: 88) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)GSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE sc9-10 DS-Cav1 A149C Y458C S46G K465Q S215P E92D-foldon-I53-50A embodiment (SEQ ID NO: 89) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIE FQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVI TSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANS VEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE sc9-10 DS-Cav1 A149C Y458C S46G K465Q S215P E92D-I53-50A-F10 embodiment (SEQ ID NO: 90) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLGALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAICSGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSRTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYCVNKQEGQSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)GSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE SC-DM(N67I, S215P)-foldon-I53-50A embodiment (SEQ ID NO: 91) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKKIKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNQARGSGSGRSLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE SC-DM(N67I, S215P)-I53-50A-F10 Embodiment (SEQ ID NO: 92) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKKIKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNQARGSGSGRSLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIR(KSDELL)GSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE SC-TM (N67I, S215P, and E487Q)-foldon-I53-50A embodiment (SEQ ID NO: 93) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKKIKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNQARGSGSGRSLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPIVNK QSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTS KTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDQFDASISQVNEKINQSLAFIR(KSDELL)GYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAV LRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE SC-TM(N67I, S215P, and E487Q)-I53-50A-F10 embodiment (SEQ ID NO:94) (MELLILKANAITTILTAVTFCFASG)QNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKKIKCNGTDAKIKLIKQELDKYKNAVTELQLLMQSTPATNNQARGSGSGRSLGFLLGVGSAIASGVAVSKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYI DKQLLPIVNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEV NLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDQFDASISQVNEKINQSLAFIR(KSDELL)GSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAI EKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV-F (SEQ ID NO: 95) with A113C, A339C, T160F, I177L-foldon-I53-50A embodiment (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNKNKCDIDD LKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPCKVSTGRHPISMVAL SPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGSGSGSEKAAKAEEAARKMEELFKKHKAVL RANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV-F (SEQ ID NO: 96) having the A113C, A339C, T160F, I177L-I53-50A F10 embodiment (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTAGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRA LNKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINIS TTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGGSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIE KAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV-F (SEQ ID NO:97) having the A113C, A120C, A339C, T160F, I177L, and Q426C-foldon-I53-50A embodiment (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTCGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNKNKCDIDD LKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPCKVSTGRHPISMVAL SPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYCLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGGYIPEAPRDGQAYVRKDGEWVLLSTFLGSHHHHHHHHGGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVL RANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV-F (SEQ ID NO:98) having the A113C, A120C, A339C, T160F, I177L, and Q426C-F10 embodiment (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCSDGPSLIKTELDLTKSALRELKTVSADQLAREEQIENPRQSRFVLGAIALGVCTAAAVTCGVAIAKTIRLESEVTAIKNALKTTNEAVSTLGNGVRVLAFAVRELKDFVSKNLTRALNKNKCDIDDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSGKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTACGINVAEQSKECNINISTTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYCLSKVEGEQHVIKGRPVSSSFDPIKFPEDQFNVALDQVFENIENSQALVDQSNRILSSAEKGNTGGSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV-F 115-BV(A185P)-foldon-I53-50A embodiment (SEQ ID NO: 99) (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRRRRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCKVSTGRHPISMVA LSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNTGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSHHHHHHHHGGSGGSGSEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGFPPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE HMPV-F 115-BV(A185P)-I53-50A-F10 version (MSWKVVIIFSLLITPQHG)LKESYLEESCSTITEGYLSVLRTGWYTNVFTLEVGDVENLTCADGPSLIKTELDLTKSALRELRTVSADQLAREEQIENPRRRRFVLGAIALGVATAAAVTAGVAIAKTIRLESEVTAIKNALKKTNEAVSTLGNGVRVLATAVRELKDFVSKNLTRAINKNKCDIPDLKMAVSFSQFNRRFLNVVRQFSDNAGITPAISLDLMTDAELARAVSNMPTSAGQIKLMLENRAMVRRKGFGILIGVYGSSVIYMVQLPIFGVIDTPCWIVKAAPSCSEKKGNYACLLREDQGWYCQNAGSTVYYPNEKDCETRGDHVFCDTAAGINVAEQSKECNINISTTNYPCKVSTGRHPISMVALSPLGALVACYKGVSCSIGSNRVGIIKQLNKGCSYITNQDADTVTIDNTVYQLSKVEGEQHVIKGRPVSSSFDPVKFPEDQFNVALDQVFESIENSQALVDQSNRILSSAEKGNTGSGGSGSGEKAAKAEEAARKMEELFKKHKIVAVLRANSVEEAIEKAVAVFAGGVHLIEITFTVPDADTVIKALSVLKEKGAIIGAGTVTSVEQCRKAVESGAEFIVSPHLDEEISQFCKEKGVFYMPGVMTPTELVKAMKLGHTILKLFPGEVVGPQFVKAMKGPFPNVKFVPTGGVNLDNVCEWFKAGVLAVGVGSALVKGTPDEVREKAKAFVEKIRGCTE
[0057] Second assembly The nanostructure of the present invention may comprise multiple copies of a first assembly of trimers and multiple copies of a second assembly. The second assembly comprises a protein-protein interface that induces multiple copies of the second polypeptide to self-associate to form the second assembly. The multiple oligomeric states of the second assembly may be compatible with nanostructure formation, including dimers (2 copies), trimers (3 copies), tetramers (4 copies), pentamers (5 copies), hexamers (6 copies), or more oligomeric states. Each copy of the second assembly further comprises a surface-exposed interface that interacts with a complementary surface-exposed interface on the trimer assembly domain. As described in King et al., Bale et al., and patent publications WO2014124301A1 and US20160122392A1, the complementary interface between the trimer assembly domain and the second assembly domain drives the assembly of multiple copies of the trimer assembly domain and the second assembly domain into the target nanostructure. In various specific embodiments, (a) when each first polypeptide is DS-Cav1-foldon-T33-31A (SEQ ID NO: 69) or DS-Cav1-T33-31A (SEQ ID NO: 70), each second polypeptide is T33-31B (SEQ ID NO: 44); (b) when each first polypeptide is DS-Cav1-foldon-T33-15B (SEQ ID NO: 71) or DS-Cav1-T33-15B (SEQ ID NO: 72), each second polypeptide is T33-15A (SEQ ID NO: 45); (c) when each first polypeptide is DS-Cav1-foldon-I53-50A (SEQ ID NO: 73) or DS-Cav1-I53-50A (SEQ ID NO: 74), each second polypeptide is I53-50B (SEQ ID NO: 8), I53-50B.1 (SEQ ID NO: 32), I53-50B.1NegT2 (SEQ ID NO: 33), or I53-50B.4PosT1 (SEQ ID NO: 34); (d) When each first polypeptide is DS-Cav1-I32-28A (SEQ ID NO: 75), each second polypeptide is I32-28B.
[0058] Assembly of fully valency nanostructures by in vitro assembly of two components In some embodiments, each trimer first assembly of nanostructures carries the same F protein as a genetic fusion; these nanostructures display the F protein in full (100%) valency. Such nanostructures are produced from purified first and second polypeptides in a process called in vitro assembly. The purified trimer first polypeptide containing the F protein is mixed with the appropriate second polypeptide in an approximately 1:1 molar ratio under aqueous conditions (see FIG. 1). The second assembly interacts with the trimer first assembly to drive the assembly of the target nanostructure. The successful assembly of the target nanostructure can be confirmed by analysis of the in vitro assembly reaction by common biological or biophysical methods used to assess the physical size of proteins or protein assemblies, including but not limited to size exclusion chromatography, native (non-denaturing) gel electrophoresis, dynamic light scattering, multi-angle light scattering, analytical ultracentrifugation, negative stain electron microscopy, cryo-electron microscopy, or X-ray crystallography. If necessary, the assembled nanostructures can be purified from other species or molecules present in the in vitro assembly reaction using preparative techniques commonly used to isolate proteins by their physical size, including but not limited to size exclusion chromatography, preparative ultracentrifugation, tangential flow filtration, or preparative gel electrophoresis. The presence of F protein in the nanostructures can be assessed by techniques commonly used to determine the identity of protein molecules in aqueous solutions, including but not limited to SDS-PAGE, mass spectrometry, protein sequencing, or amino acid analysis. The accessibility of the F protein on the particle exterior and its conformation or antigenicity can be assessed by techniques commonly used to detect the presence and conformation of antigens, including but not limited to binding by monoclonal antibodies, conformation-specific monoclonal antibodies, or antisera specific for the antigen.
[0059] In vitro assembly of partial valency nanostructures In other embodiments, the nanostructures of the present invention include one or more copies of a first assembly of trimers carrying an F protein as a genetic fusion and one or more first assemblies of trimers not carrying an F protein as a genetic fusion; these nanostructures display F protein with partial valency. These partial valency nanostructures are produced by in vitro assembly using a mixture of first polypeptides in which the proportion of the first assembly of trimers carrying an F protein as a genetic fusion is equal to the desired valency of the antigen in the resulting nanostructure. The in vitro assembly reaction typically includes all the first polypeptides and all the second polypeptides in approximately a 1:1 molar ratio. As a non-limiting example, performing an in vitro assembly reaction using a mixture of trimer assemblies in which half of the first polypeptides carry an F protein as a genetic fusion will result in an assembled nanostructure with 50% valency of F protein. That is, 50% of the sites available for F protein display on the nanostructure will be occupied. As a non-limiting example, if the nanostructure is a 120 subunit assembly with icosahedral symmetry, the nanostructure contains a total of 20 trimeric base units, and a 50% valency nanostructure displays 10 of the possible 20 F protein trimers. In this way, the ratio of the first polypeptide carrying the F protein to the first polypeptide lacking the F protein in the in vitro assembly reaction can be used to precisely adjust the valency of the F protein in the resulting nanostructure. It will be understood by those skilled in the art that it is the average valency that can be adjusted in this manner; the valency of the individual nanostructures in the mixture is distributed around the average. The successful assembly of such partial valency nanostructures can be assessed using the techniques described above for evaluating full valency nanostructures, and if necessary, the partial valency nanostructures can be purified using the methods described for purifying full valency nanostructures. The average valency of the first polypeptide carrying the F protein in a given sample can be assessed by quantitative analysis using the techniques described above for evaluating the presence of F protein in full valency nanostructures.
[0060] In vitro assembly of nanostructures simultaneously displaying multiple F proteins In other embodiments, the nanostructures of the present invention comprise two or more distinct first polypeptides carrying different F proteins as genetic fusions; these nanostructures display multiple different F proteins simultaneously on the same nanostructure. These multi-antigen nanostructures are produced by performing in vitro assembly with a mixture of first polypeptides, each of which carries one of two or more distinct F proteins as genetic fusions. The ratio of each first polypeptide in the mixture determines the average valency of each F protein in the resulting nanostructure. The in vitro assembly reaction typically has a molar ratio of all trimer first polypeptides to all second polypeptides of approximately 1:1. The presence and average valency of the first polypeptides carrying each F protein in a given sample can be assessed by quantitative analysis using the techniques described above to evaluate the presence of F proteins in nanostructures of full valency.
[0061] In various embodiments, the nanostructures have diameters between about 20 nanometers (nm) and about 40 nm, lumen widths between about 15 nm and about 32 nm, and protein shell pores with diameters between about 1 nm and about 14 nm in their longest dimension.
[0062] In one embodiment, the nanostructure has icosahedral symmetry. In this embodiment, the nanostructure can include 60 copies of a first polypeptide and 60 copies of a second polypeptide. In one such embodiment, the number of identical first polypeptides in each first assembly is different from the number of identical second polypeptides in each second assembly. For example, in one embodiment, the nanostructure includes 12 first assemblies and 20 second assemblies; in this embodiment, each first assembly can include, for example, 5 copies of an identical first polypeptide, and each second assembly can include, for example, 3 copies of an identical second polypeptide. In another embodiment, the nanostructure includes 12 first assemblies and 30 second assemblies; in this embodiment, each first assembly can include, for example, 5 copies of an identical first polypeptide, and each second assembly can include, for example, 2 copies of an identical second polypeptide. In further embodiments, the nanostructure comprises 20 first assemblies and 30 second assemblies; in this embodiment, each first assembly can comprise, for example, three copies of an identical first polypeptide, and each second assembly can comprise, for example, two copies of an identical second polypeptide. All of these embodiments can form a synthetic nanomaterial with regular icosahedral symmetry. In various further embodiments, the oligomeric state of the first and second polypeptides is as follows: I53-34A: trimer + I53-34B: pentamer; I53-40A: Pentamer + I53-40B: Trimer; I53-47A: trimer + I53-47B: pentamer; I53-50A: trimer + I53-50B: pentamer; I53-51A: trimer + I53-51B: pentamer; I32-06A: Dimer + I32-06B: Trimer; I32-19A: trimer + I32-19B: dimer; I32-28A: trimer + I32-28B: dimer; I52-03A: Pentamer + I52-03B: Dimer; I52-32A: dimer + I52-32B: pentamer; and I52-33A: Pentamer + I52-33B: Dimer
[0063] In another embodiment, the nanostructure of any embodiment or combination of embodiments of the present invention has one or more of the following characteristics, each of which is demonstrated in the examples below: (a) binding to a pre-fusion F-specific antibody (including but not limited to monoclonal antibody D25); (b) forming a symmetrical structure (including, but not limited to, an icosahedral structure); (c) being stable at 50°C; and / or (d) It is stable in 2.25 M guanidine hydrochloride.
[0064] In another aspect, the present invention provides an isolated nucleic acid encoding the fusion protein of the present invention. The isolated nucleic acid sequence may comprise RNA or DNA. As used herein, an "isolated nucleic acid" is a nucleic acid that is removed from the nucleic acid sequence that normally surrounds it in a genome or cDNA sequence. Such an isolated nucleic acid sequence may comprise additional sequences useful for facilitating the expression and / or purification of the encoded protein, including, but not limited to, polyA sequences, modified Kozak sequences, and sequences encoding epitope tags, export signals, and secretion signals, nuclear localization signals, and plasma membrane localization signals. Based on the teachings herein, it will be clear to one skilled in the art what nucleic acid sequences encode the proteins of the present invention.
[0065] In a further aspect, the present invention provides a recombinant expression vector comprising an isolated nucleic acid of any embodiment or combination of embodiments of the present invention operably linked to a suitable regulatory sequence. A "recombinant expression vector" includes a vector in which a nucleic acid coding region or a nucleic acid encoding gene is operably linked to any regulatory sequence capable of expressing the gene product. A "regulatory sequence" operably linked to a nucleic acid sequence of the present invention is a nucleic acid sequence capable of expressing a nucleic acid molecule. Regulatory sequences need not be contiguous with a nucleic acid sequence, so long as they function to direct its expression. Thus, for example, intervening sequences that are not translated but are transcribed can be present between the promoter sequence and the nucleic acid sequence, and the promoter sequence can still be considered "operably linked" to the coding sequence. Other such regulatory sequences include, but are not limited to, polyadenylation signals, termination signals, and ribosome binding sites. Such expression vectors can be of any type known in the art, including, but not limited to, plasmids and viral expression vectors. The regulatory sequences used to drive expression of the disclosed nucleic acid sequences in mammalian systems can be constitutive (driven by any of a variety of promoters, including but not limited to, CMV, SV40, RSV, actin, EF) or inducible (driven by any of a number of inducible promoters, including but not limited to, tetracycline-responsive, ecdysone-responsive, steroid-responsive promoters).The construction of expression vectors for use in transfection of prokaryotic cells is also well known in the art and can therefore be carried out by standard techniques (see, for example, Sambrook, Fritsch, and Maniatis, in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989; Gene Transfer and Expression Protocols, pp. 109-128, ed. EJ Murray, The Humana Press Inc., Clifton, NJ) and Ambion 1998 catalog (Ambion, Austin, TX)). Expression vectors must be replicable in the host cell, either as episomes or by integration into the host chromosomal DNA. In a preferred embodiment, the expression vector comprises a plasmid. However, the invention is intended to include other expression vectors that serve equivalent functions, such as viral vectors.
[0066] In another aspect, the invention provides a host cell transfected with a recombinant expression vector disclosed herein, the host cell can be either a prokaryotic or eukaryotic cell, such as a mammalian cell. The cell can be transiently or stably transfected. Such transfection of expression vectors into prokaryotic and eukaryotic cells can be carried out by any technique known in the art, including, but not limited to, standard bacterial transformation, calcium phosphate co-precipitation, electroporation, or liposome-, DEAE-dextran-, polycation-, or viral-mediated transfection (see, for example, Molecular Cloning: A Laboratory Manual (Sambrook et al., 1989, Cold Spring Harbor Laboratory Press; Culture of Animal Cells: A Manual of Basic Technique, 2nd Ed. (RI Freshney. 1987. Liss, Inc. New York, NY). A method for producing the polypeptides of the invention is a further part of the invention. The method comprises the steps of (a) culturing a host of this aspect of the invention under conditions allowing expression of the polypeptide, and (b) optionally recovering the expressed polypeptide.
[0067] In a further aspect, the present invention provides an immunogenic composition comprising an effective amount of the nanostructures of any embodiment or combination of embodiments of the present invention, and a pharma- ceutically acceptable carrier. The composition may include (a) a lyoprotectant; (b) a surfactant; (c) a bulking agent; (d) a tonicity modifier; (e) a stabilizer; (f) a preservative, and / or (g) a buffer.
[0068] In some embodiments, the buffer in the pharmaceutical composition is a Tris buffer, a histidine buffer, a phosphate buffer, a citrate buffer, or an acetate buffer. The composition may also include a lyoprotectant (e.g., sucrose, sorbitol, or trehalose). In certain embodiments, the composition includes a preservative (e.g., benzalkonium chloride, benzethonium, chlorhexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercuric nitrate (II), thyromesal, benzoic acid, and various mixtures thereof). In other embodiments, the composition includes a bulking agent such as glycine. In yet other embodiments, the composition comprises a surfactant (e.g., polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80 polysorbate-85, poloxamer-188, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleate, or a combination thereof). The composition may also comprise a tonicity adjuster (e.g., a compound that renders the formulation substantially isotonic or isosmotic with human blood). Exemplary tonicity adjusters include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine, and arginine hydrochloride. In other embodiments, the composition further comprises a stabilizer (e.g., a molecule that substantially prevents or reduces chemical and / or physical instability of the nanostructures in lyophilized or liquid form). Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride.
[0069] The nanostructures may be the only active agent in the composition, or the composition may further include one or more other agents appropriate for the intended use, including, but not limited to, adjuvants that generally stimulate the immune system to improve the overall immune response. Any suitable adjuvant may be used. The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. Exemplary adjuvants include Adju-Phos™, Adjumer™, albumin-heparin microparticles, algae glucan, argamulin, alum, antigen formulations, AS-2 adjuvant, autologous dendritic cells, autologous PBMCs, Abridine™, B7-2, BAK, BAY R1005, bupivacaine, bupivacaine-HCl, BWZL, calcitriol, calcium phosphate gel, CCR5 peptide, CFA, cholera holotoxin (CT) and cholera toxin B subunit (CTB), cholera toxin A1-subunit-protein A. D-fragment fusion protein, CpG, CRL1005, cytokine-containing liposomes, D-murapalmitin, DDA, DHEA, diphtheria toxoid, DL-PGL, DMPC, DMPG, DOC / alum complex, fowlpox, Freund's complete adjuvant, gamma inulin, Gerbu adjuvant, GM-CSF, GMDP, hGM-CSF, hIL-12 (N222L), hTNF-α, IFA, IFN-γ-containing pcDNA3, IL-12 DNA, IL-12 plasmid, IL-12 / GMCSF Plasmid (Sykes), IL-2 containing pcDNA3, IL-2 / Ig plasmid, IL-2 / Ig protein, IL-4, IL-4 containing pcDNA3, Imiauimod™, ImmTher™, immunoliposomes containing antibodies against costimulatory molecules, interferon-gamma, interleukin-1β, interleukin-12, interleukin-2, interleukin-7, ISCOM™, Iscoprep7.0.3™, keyhole limpet hemocyanin, lipid-based adjuvants, liposomes, loxoribine, LT(R192G), LT-OA or LT Oral adjuvant, LT-R192G, LTK63, LTK72, MF59, MONTANIDE ISA 51, MONTANIDE ISA 720, MPL.TM., MPL-SE, MTP-PE, MTP-PE liposomes, muramethide, murapalmitine, NAGO, nCT native cholera toxin, non-ionic surfactant vesicles, non-toxic mutant E112K of cholera toxin mCT-E112K, p-hydroxybenzoic acid methyl ester, pCIL-10, pCIL12, pCMVmCAT1, pCMVN, Peptomer-NP, Pleuran, PLG, PLGA, PGA, and PLA, Pluronic L121, PMMA, PODDS™, Poly rA:Poly Adjuvants include, but are not limited to, rU, polysorbate 80, protein cocreate, QS-21, QuadriA saponin, Quil-A, RehydragelHPA, RehydragelLV, RIBI, Ribilike adjuvant system (MPL, TMD, CWS), S-28463, SAF-1, Sclavo peptides, Sendai proteoliposomes, Sendai containing lipid matrix, Span85, Specol, squalane 1, squalene 2, stearyl tyrosine, tetanus toxoid (TT), Theramide™, threonyl muramyl dipeptide (TMDP), Ty particles, and Walter Reed liposomes. The choice of adjuvant depends on the subject being treated. Preferably, a pharma- ceutically acceptable adjuvant is used.
[0070] In another aspect, the invention provides a method of generating an immune response in a subject against a paramyxovirus and / or pneumovirus F protein, the method comprising administering to the subject an effective amount of an immunogenic composition of any embodiment or combination of embodiments of the invention to generate an immune response. In a further aspect, the invention provides a method of treating or preventing a paramyxovirus and / or pneumovirus infection in a subject, the method comprising administering to the subject an effective amount of an immunogenic composition of any embodiment or combination of embodiments of the invention, thereby treating or preventing a paramyxovirus and / or pneumovirus infection in the subject.
[0071] In one embodiment, the paramyxovirus and / or pneumovirus comprises respiratory syncytial virus. "Respiratory syncytial virus" and "RSV" refer to a single-stranded negative-stranded RNA virus that causes respiratory disease, especially in children. When the method includes treating RSV infection, the immunogenic composition is administered to a subject who is already infected with RSV and / or suffers from symptoms that indicate that the subject is likely infected with RSV, including but not limited to lower respiratory tract infection, upper respiratory tract infection, bronchiolitis, pneumonia, fever, fatigue, loss of appetite, recurrent wheezing, and asthma. As used herein, "treating" or "treatment" includes, but is not limited to, achieving one or more of the following: (a) reducing paramyxovirus and / or pneumovirus titer in a subject; (b) limiting any increase in paramyxovirus and / or pneumovirus titer in a subject; (c) reducing the severity of paramyxovirus and / or pneumovirus symptoms; (d) limiting or preventing the occurrence of paramyxovirus and / or pneumovirus symptoms following infection; (e) inhibiting the worsening of paramyxovirus and / or pneumovirus symptoms; (f) limiting or preventing the recurrence of paramyxovirus and / or pneumovirus symptoms in a subject who previously had symptoms of paramyxovirus and / or pneumovirus infection; and / or promoting maternal transmission of paramyxovirus and / or pneumovirus antibodies to the infant (following maternal immunization).
[0072] When the method includes restricting paramyxovirus and / or pneumovirus infection, the immunogenic composition is administered prophylactically to subjects who are not known to be infected with paramyxovirus and / or pneumovirus but may be at risk of exposure.As used herein, "restriction" refers to restricting RSV infection in subjects at risk of RSV infection.Particularly high-risk groups include children under 18 years old (especially infants under 3 years old), adults over 65 years old, and individuals suffering from any type of immunodeficiency.
[0073] As used herein, "effective amount" refers to an amount of the immunogenic composition effective in treating and / or limiting RSV infection. The immunogenic composition is typically formulated as a pharmaceutical composition (such as the pharmaceutical composition disclosed above) and can be administered via any suitable route (including orally, parentally, inhalation spray, rectally, or topically) in a dosage unit formulation containing conventional pharma- ceutically acceptable carriers, adjuvants, and vehicles. The term parenteral as used herein includes subcutaneous, intravenous, intraarterial, intramuscular, intrasternal, intratendinous, intraspinal, intracranial, intrathoracic, infusion techniques, or intraperitoneally. The polypeptide composition can also be administered via microspheres, liposomes, immune stimulating complexes (ISCOMs), or other microparticulate delivery systems or sustained release formulations that are introduced into appropriate tissues (such as blood). Dosage regimens can be adjusted to obtain the optimal desired response (e.g., therapeutic or prophylactic response). A suitable dosage range may be, for example, 0.1 ug / kg body weight to 100 mg / kg body weight of F protein or antigenic fragment thereof. The composition may be delivered in a single bolus or may be administered more than once (e.g., 2, 3, 4, 5, or more times) as determined by the attending physician.
[0074] In one embodiment, administration produces paramyxovirus and / or pneumovirus neutralizing antibodies in the subject. In another embodiment, the neutralizing antibodies have a titer of at least 1,000 (1 / ID 50 ) in the serum of the subject; in other embodiments, neutralizing antibodies are present in the serum of the subject at a titer of 2,000 or 5,000.
[0075] Working Example method: Expression and screening of trimeric building blocks containing F protein and trimeric assembly domains Human codon-optimized sequences for the trimeric building blocks containing or lacking the DS-Cav1 fusion were ordered from Genscript. The building blocks of single-component nanostructures (i.e., I3-01) were cloned into a pcDNA3.1 vector (ThermoFisher Scientific) containing one CMV promoter, while the building blocks of two-component nanostructures (e.g., I53-50) were cloned into a pBudCE4.1™ vector (ThermoFisher Scientific) containing both the CMV promoter and the EF-1α promoter. Recombinant proteins were expressed by transient transfection of Expi293F™ cells (ThermoFisher Scientific) using polyethylenimine (PEI). Cell cultures were harvested by centrifugation 5 days after transfection. Secreted proteins were analyzed by either ELISA using direct coating of cell supernatants or sandwich ELISA. Briefly, 96-well MaxiSorp™ plates (Nunc) were coated with cell supernatants for direct ELISA and with mouse anti-His tag monoclonal antibody (ThermoFisher Scientific) for sandwich ELISA. Secreted proteins were detected using human palivizumab, MPE8, RSD5, and D25 monoclonal antibodies. Transfected Expi293F cells were fixed and permeabilized using BD cytofix / cytoperm (BD Biosciences), incubated with human palivizumab, MPE8, and D25 monoclonal antibodies, and stained with Alexa Fluor 647-conjugated anti-human IgG antibody (Jackson ImmunoResearch). Stained cells were counted on a FACS Fortessa™ flow cytometer (BD Biosciences). Analysis was performed using FlowJo™ software. Cell lines were routinely tested for mycoplasma contamination.
[0076] Expression and purification of DS-Cav1-I53-50A Lentivirus was produced by transient transfection of 293T (ATCC) cells with linear 25 kDa polyethyleneimine (PEI; Polysciences). Briefly, 4 × 10 6 Cells were plated on 10 cm tissue culture plates. After 24 hours, 3 μg of psPAX2, 1.5 μg of pMD2G (Addgene™ plasmid no. 12260 and no. 12259, respectively), and 6 μg of lentiviral vector plasmid were mixed with 500 μl diluent (5 mM HEPES, 150 mM NaCl, pH=7.05) and 42 μl of PEI (1 mg / ml) and incubated for 15 minutes. The DNA / PEI complex was then added dropwise to the plate. 48 hours after transfection, lentivirus was harvested and concentrated 100-fold by low-speed centrifugation at 8000 g for 18 hours. 10×10 6 Target cell lines were transduced in 125 mL shake flasks containing 10 mL growth medium containing cells. 100 uL of 100x lentivirus was added to the flask and cells were incubated for 4-6 hours in 8% CO2 at 37 °C with shaking (225 rpm). After 4-6 hours, 20 mL of growth medium was added to the shake flask.
[0077] Transduced cells were cultured at 1 × 10 6 The cells were expanded every other day to a density of 100 cells / ml. After a total of 17 days of incubation, the final cell concentration (approximately 5 × 10 6The medium was harvested after measuring the number of cells / mL) and viability (approximately 90% viable). The culture supernatant was harvested by low-speed centrifugation to remove the cells from the supernatant. NaCl and NaN3 were added to a final concentration of 250 mM and 0.02%, respectively. The supernatant was loaded at 5 ml / min onto one 5 mL HisTrap™ FF Crude column (GE Healthsciences) by AKTA Pure™ (GE Healthsciences). The nickel elution was applied to a HiLoad™ 16 / 600 Superdex 200pg column (GE Healthsciences) to further purify the target protein by size-exclusion chromatography. The target protein purified by size-exclusion was flash frozen in liquid nitrogen and stored at -80°C.
[0078] In vitro assembly of DS-Cav1-bearing nanostructures Particles with 100% valency (20 DS-Cav1 trimers per icosahedral nanostructure) were prepared by mixing 50 μM each of DS-Cav1-foldon-I53-50A trimers and I53-50B.4PT1 pentamers and incubating overnight at 4 °C with rocking. In some cases, assembled nanostructures were purified from excess components remaining in the in vitro assembly reaction in a buffer containing 25 mM Tris (pH 8), 250 mM NaCl, 5% glycerol using a GE Sephacryl S-500 HR 16 / 60 column. Sample loading and SEC fractions were analyzed by SDS-PAGE in the presence and absence of reducing agents. Peak fractions were pooled and concentrated using a GE Vivaspin™ 20 30 kDa MWCO centrifugal filter and quantified using an Agilent 8454 spectrophotometer.
[0079] Particles with 66% valency (approximately 14 DS-Cav1 trimers per icosahedral nanostructure) were prepared by mixing 50, 25, and 75 μM of DS-Cav1-foldon-I53-50A trimer, I53-50A trimer, and I53-50B.4PosT1 pentamer, respectively. Particles with 33% valency (approximately 7 DS-Cav1 trimers per icosahedral nanostructure) were prepared by mixing 25, 50, and 75 μM of DS-Cav1-foldon-I53-50A trimer, I53-50A trimer, and I53-50B.4PosT1 pentamer, respectively. In vitro assembly reactions were incubated overnight at 4 °C with rocking. In some cases, assembled nanostructures were purified from excess components remaining in the in vitro assembly reaction in a buffer containing 25 mM Tris (pH 8), 250 mM NaCl, 5% glycerol using a GE Sephacryl™ S-500 HR16 / 60 column. Sample loading and SEC fractions were analyzed by SDS-PAGE in the presence and absence of reducing agents. Peak fractions were pooled and concentrated using a GE Vivaspin™ 20 30 kDa MWCO centrifugal filter and quantified using an Agilent 8454 spectrophotometer after centrifugation at approximately 21,000 g for 10 min at 4° C. Samples were then transferred in 1 mL aliquots to cryogenic storage tubes at 1.1 mg / mL for 33% valency particles and 0.6 mg / mL for 66% valency particles, flash frozen in liquid nitrogen, and stored at −80° C.
[0080] DS-Cav1-bearing nanostructures by electron microscopy Samples were prepared for negative stain EM by diluting to 0.01 mg / mL using 25 mM Tris (pH 8), 250 mM NaCl, 5% glycerol, and incubating 3.5 μL on a glow-discharged copper carbon-coated grid for 20 seconds before blotting with a piece of Whatman No. 1 filter paper. Within seconds of blotting the sample, a 3.5 μL drop of stain (2% w / v uranyl formate) was deposited and immediately blotted, followed by a second cycle of staining / blotting.
[0081] Circular dichroism (CD) spectropolarimetric analysis F protein (0.5 mg ml -1 CD spectra from 195-260 nm were recorded on a Chirascan™ spectropolarimeter (Applied Photophysics) with a bandwidth of 1 nm, a step size of 0.5 nm, and 1 sec / step over the wavelength range of 195-260 nm. The spectrum in the far UV range required an average of 3 scans, which was subtracted from a blank spectrum performed with buffer. Thermal denaturation was monitored by scanning at 1°C intervals after 1 min equilibration at each temperature. Data were fitted to a simple linear curve. ΔA222 values are shown on the y-axis as a percentage of the value recorded at 20°C.
[0082] Enzyme-linked immunosorbent assay (ELISA) To test for specific binding of antibodies or sera, 96-well MaxiSorp™ plates (Nunc) were loaded with either F protein and trimeric assembly domain or 2 μg ml -1 Plates were coated with serial dilutions of tissue culture supernatant from cells expressing the trimeric building block containing the following purified proteins: Ds-Cav1 with foldon, Ds-Cav1 fused to the first polypeptide of the trimer, or nanostructures displaying DS-Cav1. Plates were blocked with 1% bovine serum albumin (BSA) and incubated with titrated antibodies (D25, MPE8, Palivizumab, RSD5) or mouse serum, followed by incubation with AP-conjugated goat anti-human IgG (Southern Biotech, 2040-04) or goat anti-mouse IgG (Southern Biotech, 1030-04). Plates were then washed with PBS buffer (Gibco, Invitrogen), 0.05% Tween-20 and substrate (p-NPP, Sigma) were added, and plates were read at 405 nm.
[0083] Surface Plasmon Resonance (SPR) The experiments were carried out in PBS buffer (Gibco, Invitrogen), 0.05% Tween-20 at 25°C on a ProteON™ XPR-36 instrument (Bio-Rad Laboratories). D25mAb was immobilized on the GLM sensor chip surface by amine coupling at 1000 response units (RU), and a blank surface without protein was created under identical coupling conditions to serve as a reference. Monoclonal antibodies (D25, MPE8, Palivizumab, and 131-2a) were injected into the different sensor channels at a flow rate of 100 μl / min and a concentration of 50 nM. Data were processed using Proteon software and double referenced by subtracting the blank surface and buffer only injections before local fitting of the data.
[0084] Vaccination and serological analysis Female BALB / c mice, 6-9 weeks of age, were obtained from ENVIGO Laboratories (Italy). Total proteins were formulated with AddaVax™ adjuvant (Invivogen) according to the manufacturer's instructions. Mice were immunized subcutaneously (sc) on days 0, 14, and 28 with a total protein dose equivalent to 5 μg of DS-Cav1 antigen equivalent in PBS containing 50% AddaVax™. Mice were bled on days 24 and 40. Binding and neutralization titers were measured using collected sera. Binding titers were measured by coating with 3 μg / ml of DS-Cav1, I53-50 nanostructure, or I53-50 nanostructure subunit.
[0085] Virus neutralization assay and microscopic analysis Neutralization of RSV infection by sera was measured using a microneutralization flow cytometry-based assay. Serial dilutions of sera were pre-incubated with RSV for 1 h at 37° C. and added to 10,000 HEp-2 (ATCC® CCL-23™) cells / well in 96-well flat-bottom plates (MOI of 1). After 24 h, cells were washed, detached, and fixed with 2% formaldehyde. The percentage of GFP-positive cells was measured by high-throughput FACS using an Intellicyt coupled to an automation platform. 50% infection neutralization at tissue culture inhibitory dilution (TCID 50 ) was calculated by nonlinear regression using Prism 7 (GraphPad Software).
[0086] Immunization of non-human primates (NHPs) Rhesus macaques were immunized im (right quadriceps) with trimeric DS-Cav1 (50 μg; n=4) or DS-Cav1-foldon-I53-50 nanostructures (96 μg, containing 50 μg of the indicated DS-Cav1; n=5) formulated in the MF59-like adjuvant SWE at weeks 0 and 4. Sera were obtained at weeks 6 and 16 for serological analysis.
[0087] Stability of DS-Cav1-bearing nanostructures by relative binding to D25 The experiments were carried out in PBS buffer (Gibco, Thermo Fisher Scientific) and 0.05% Tween-20 (Sigma) at 20°C on a ProteON™ XPR-36 instrument (Bio-Rad Laboratories). 100 nM D25 antibody was immobilized on the GLM sensor chip surface by amine coupling (EDC / NHS chemistry) and a blank surface without antibody was created under identical coupling conditions to serve as a reference. Analyte proteins (soluble DS-Cav1, soluble DS-Cav1-I53-50A, and DS-Cav1-foldon-I53-50 nanostructures) heat-stressed for 1 h at different temperatures (20, 50, 70, or 80°C) were injected into the different sensor channels at a flow rate of 100 μl / min and a concentration of 50 nM. Data were processed using Proteon software and double-referenced by subtracting the blank surface and buffer-only injections before local fitting of the data.
[0088] Chemical denaturation of nanostructure-associated proteins Trimeric DS-Cav1, DS-Cav1-I53-50A, DS-Cav1-I53-50, I53-50, trimeric I53-50A, or pentameric I53-50B.4PT1 were diluted to a final concentration of 2.5 μM in 25 mM Tris (pH 8), 250 mM NaCl, 5% glycerol with various concentrations of guanidine hydrochloride in increments of 0.25 M ranging from 0 to 6.5 M. Samples were prepared in triplicate and incubated for 16 h at ambient temperature. Autofluorescence was measured for each protein and each guanidine hydrochloride concentration for each replicate in a Cary Eclipse fluorescence spectrophotometer. A Peltier controller was used in the cell holder to maintain 25 °C throughout the entire experiment. A 10 mm cell (Agilent Cuvette, part number 6610021600) was used to collect fluorescence spectra excited at 290 nm and scanned from 310 nm to 510 nm emission with a bandwidth of 1 nm at a speed of 60 nm / min.
[0089] statistical analysis No statistical methods were used to predetermine sample size. Data were analyzed in Prism 6 (GraphPad™ Software) using the two-tailed nonparametric Mann-Whitney U test for two-group comparisons or the Kruskal-Wallis test (with Dunn's posttest) when comparing three or more groups.
[0090] result Trimeric base unit containing F protein and trimer assembly domain Several trimeric building blocks, each containing an F protein genetically fused to a trimer assembly domain, were found to be secreted from HEK293F cells, and the F protein was in a fully folded prefusion conformation as judged by prefusion-specific monoclonal antibody binding in an ELISA assay. Figure 2 shows example ELISA data analyzing supernatants of HEK293F cells expressing DS-Cav1-foldon, DS-Cav1-foldon-T33-31A, and DS-Cav1-T33-31A. Several other trimeric building blocks detectably secreted fully folded prefusion F protein.
[0091] Expression and purification of DS-Cav1-foldon-I53-50A A lentiviral vector encoding DS-Cav1-foldon-I53-50A was used to transduce HEK293F cells for large-scale expression. Secreted proteins were purified from tissue culture supernatants by immobilized metal affinity chromatography and size-exclusion chromatography. Size-exclusion chromatograms (Figure 3) showed that the purified proteins formed a single monodisperse species.
[0092] Expression and purification of I53-50B.4PT1 I53-50B.4PT1, a pentameric protein containing a second assembly domain that interacts with the trimeric assembly domain in I53-50A or DS-Cav1-foldon-I53-50A to drive the assembly of icosahedral I53-50-based nanostructures, was expressed and purified as described in Bale et al. and patent publication US20160122392A1.
[0093] In vitro assembly and characterization of DS-Cav1-bearing I53-50 nanostructures I53-50 is a 120-subunit bicomponent nanostructure with icosahedral symmetry containing 20 trimeric (I53-50A) and 12 pentameric (I53-50B) basic units as recently described by Bale et al. The N-terminus of I53-50A is exposed on the outer surface of the I53-50 nanostructure, allowing the display of antigens on the outer surface of the nanostructure by genetic fusion to the N-terminus of I53-530A. Purified DS-Cav1-foldon-I53-50A and I53-50B.4PT1 were assembled in vitro to form 120-subunit icosahedral nanostructures displaying various amounts of DS-Cav1 on the outer surface of the nanostructure by mixing the two purified proteins in various molar ratios. In separate preparations, nanostructures displaying DS-Cav1 at valencies of 100% (20 trimers), 66% (approximately 14 trimers), and 33% (approximately 7 trimers) were prepared as described above. The species present in the in vitro assembly reactions after overnight incubation were assessed by several techniques, including size-exclusion chromatography-multi-angle light scattering (SEC-MALS), dynamic light scattering, and UV / visible spectroscopy. Assembled 120-subunit nanostructures were purified from the in vitro assembly reactions using size-exclusion chromatography (an example chromatogram obtained using a 100% valency nanostructure is shown in Figure 4). The purified nanostructures were characterized by negative staining electron microscopy, which revealed monodisperse particle regions where DS-Cav1 was clearly visible as spikes protruding outward from the core icosahedral I53-50 assembly (an example of a micrograph obtained using 100% valency particles is shown in Figure 5). ELISA assays using a monoclonal antibody specific for the prefusion conformation confirmed that DS-Cav1 displayed on the nanostructure outer surface as described above was fully folded and antigenically intact (Figure 6).Surface plasmon resonance experiments evaluating the kinetics of monoclonal antibody binding revealed that the dissociation of the antibody from 100% valency DS-Cav1-foldon-I53-50 nanostructures was slower than that from DS-Cav1-foldon trimers, likely due to the avidity effect resulting from the multivalent presentation of DS-Cav1 on the nanostructure outer surface (Figure 6). Collectively, these experiments confirmed that DS-Cav1-foldon-I53-50 nanostructures form monodisperse icosahedral nanostructures displaying well-folded, antigenically intact DS-Cav1 trimers on their outer surface. These findings motivated us to perform experiments to evaluate the utility of DS-Cav1-foldon-I53-50 nanostructures as immunogens to induce humoral immune responses against DS-Cav1 in animals.
[0094] Immunogenicity of DS-Cav1-foldon-I53-50 nanostructures DS-Cav1-foldon-I53-50 nanostructures displaying DS-Cav1 at binding valencies of 33%, 66%, and 100% were injected into mice using the prime-boost strategy described above. Additional groups of mice were injected with trimeric DS-Cav1-foldon as a benchmark for humoral immune responses induced against DS-Cav1 by the nanostructures or with I53-50 nanostructures not displaying DS-Cav1 as a negative control for DS-Cav1-specific responses. ELISA assays of serum extracted from mice at defined time points after injection were used to measure the DS-Cav1-specific antibody titers present in the serum of injected animals (Figure 7). As expected, serum from animals injected with I53-50 nanostructures not displaying DS-Cav1 did not contain antibodies specific for DS-Cav1. In accordance with previous results (McClellan et al.), trimeric DS-Cav1-foldon induced DS-Cav1-specific antibodies. DS-Cav1 nanostructures with valencies of 33%, 66%, and 100% all induced higher DS-Cav1-specific antibody titers than the trimeric DS-Cav1-foldon, and the antibody titers increased as the DS-Cav1 valency increased. The DS-Cav1-specific titers were approximately 2.5-fold higher on average in mice injected with DS-Cav1-foldon-I53-50 nanostructures with valency of 100% compared to DS-Cav1. These results demonstrate that immunogens in which paramyxovirus F protein is multivalently displayed on self-assembled protein nanostructures can induce higher humoral immune responses when injected into animals.
[0095] Sera from mice injected with the above series of immunogens were also evaluated for the presence of neutralizing antibody titers using a standard neutralization assay in HEp-2 cells (Figure 8). The trends in serum neutralizing antibody titers correlated well with those seen in DS-Cav1 specific binding antibody titers. Sera from animals injected with I53-50 nanostructures not displaying DS-Cav1 did not neutralize the virus, consistent with the lack of DS-Cav1 specific antibodies in these sera. Sera from animals injected with trimeric DS-Cav-1-foldon neutralized the virus with mean titers (1 / ID50 ) neutralized the virus at 3,030. DS-Cav1-I53-50 nanostructures with binding valencies of 33%, 66%, and 100% induced higher neutralizing antibody titers than the trimeric DS-Cav1-foldon, with mean titers of 9,400, 20,000, and 30,500, respectively. These results demonstrate that the virus is more effectively neutralized by the higher humoral response induced by the immunogen multivalently displayed on the self-assembling protein nanostructure of paramyxovirus F protein.
[0096] To evaluate its immunogenicity in the primate immune system, the DS-Cav1-foldon-I53-50 nanostructure was also injected into rhesus macaques. The animals were intramuscularly injected at weeks 0 and 4 with either free DS-Cav1 trimers or DS-Cav1-foldon-I53-50 nanostructures displaying DS-Cav1 at 100% valency. In both cases, the dose of DS-Cav1 antigen was 50 μg and the immunogen was formulated with the MF59-like squalene-based oil-in-water emulsion adjuvant SWE. Sera obtained from animals at weeks 6 and 16 were evaluated for anti-DS-Cav1 and RSV-neutralizing antibody titers (Figure 9). The results mirrored those obtained in mice. At week 16, the mean anti-DS-Cav1 antibody titer in animals injected with DS-Cav1-foldon-I53-50 nanostructures was 4-fold higher than in animals injected with trimeric DS-Cav1. At week 16, the mean RSV-neutralizing antibody titer in animals injected with DS-Cav1-foldon-I53-50 nanostructures was 16-fold higher than in animals injected with trimeric DS-Cav1. These results demonstrate that in the primate immune system, immunogens multivalently displayed on self-assembling protein nanostructures of paramyxovirus F proteins induce more robust humoral immune responses (including higher levels of virus-neutralizing antibodies) than trimeric paramyxovirus F proteins alone.
[0097] Physical stabilization of DS-Cav1 by fusion to I53-50A Given the important antigenic properties of pre-fusion F, we used two orthogonal approaches to measure the physical stability of DS-Cav1 when fused to I53-50A and / or further assembled into icosahedral nanostructures. The first assay measured the duration of binding by a pre-fusion specific mAb (D25) after temperature stress (an approach previously used to characterize pre-fusion F stability) (McLellan et al., 2013; Joyce et al., 2016; Krarup et al., 2015). Samples of trimeric DS-Cav1, trimeric DS-Cav1-I53-50A, and DS-Cav1-I53-50 nanostructures containing equal concentrations (50 nM) of DS-Cav1 were divided into four aliquots and incubated at 20, 50, 70, or 80 °C for 1 h. After cooling to room temperature, D25 binding was assayed by surface plasmon resonance (SPR). We found that all samples bound D25 equally at 20°C and 50°C, but lost most of their reactivity to D25 after 1 h at 80°C (Figure 10), as previously reported for DS-Cav1 (McLellan et al., 2013; Joyce et al., 2016). Interestingly, D25 also failed to bind to trimeric DS-Cav1 incubated at 70°C for 1 h, whereas trimeric DS-Cav1-I53-50A and DS-Cav1-I53-50 nanostructures retained 50% and 80% of their respective binding signals (Figure 10). Although the multivalency of the DS-Cav1-I53-50 nanostructures complicates a direct quantitative comparison with trimeric DS-Cav1, these results indicate that genetic fusion to the I53-50A trimer further stabilizes the prefusion conformation of DS-Cav1 and suggest that this increased stability is maintained in the context of the assembled nanostructured immunogen.
[0098] We used chemical denaturation in guanidine hydrochloride (GdnHCl) monitored by tryptophan autofluorescence as a second antibody-independent technique to assess physical stability. Analysis of the fluorescence emission from DS-Cav1 incubated in 0-6.5 M GdnHCl revealed that the protein undergoes two slightly different transitions, one between 0.25 M and 2.25 M GdnHCl and the other between 2.25 M and 5.75 M GdnHCl (Figure 11). In contrast, for trimeric DS-Cav1-I53-50A, only a single transition is evident, occurring between 2.25 M and 6.25 M GdnHCl (Figure 11). It is not clear at this time whether the transition at lower [GdnHCl] observed for DS-Cav1 is absent in trimeric DS-Cav1-I53-50A or whether it is simply shifted to higher [GdnHCl]. However, it was clear that the native conformation of DS-Cav1 was stabilized by genetic fusion to the trimeric I53-50A, mirroring the results obtained by measuring D25 binding after temperature stress. Comparison of data for DS-Cav1-I53-50 nanostructures and I53-50 nanostructures alone (lacking fused DS-Cav1) showed that stabilization was maintained upon assembly into icosahedral nanostructures (Figure 11). This effect likely stems from the extreme stability of the I53-50A trimer. I53-50A is derived from the KDPG aldolase of the hyperthermophilic bacterium T. maritima and only began to change fluorescence at very high (>5.75 M) GdnHCl concentrations (Figure 11).
[0099] We made further constructs to assess the number of GS repeats and the need for a stabilizing domain such as the Foldon portion. Sequence information
[0100] [Table 3]
[0101] The study was based on expression yields in small-scale transient transfections. Plasmids capable of expressing the relevant constructs were transformed into NEB5α E. coli cells and selected on LB+carbenicillin agar plates. 1 mL cultures were prepared by plating bacterial colonies on TB medium and selecting again with 50ug / mL carbenicillin. Plasmids were purified from E. coli cultures using the Qiagen Mini Prep kit according to its protocol. Expi293F™ cells (ThermoFisher) were grown in Expi293™ Expression Medium (ThermoFisher) supplemented with penicillin (100u / mL) and streptomycin (100μg / mL) at 8% CO2 and 37°C with shaking at 125 rpm.
[0102] The day before transfection, cells were seeded at a concentration of 2E6 cells / mL. On the day of transfection, cells were counted by Countess II (ThermoFisher) with trypan blue to determine cell viability. The cell concentration was adjusted to 2.5E6 cells / mL, and cells were plated in a volume of 1 mL in non-treated 12-well plates (Corning). 1 μg of DNA plasmid was transfected per well using Expifectamine™ (ThermoFisher) according to the manufacturer's instructions. Enhancer (a component of ThermoFisher's Expifectamine™ Transfection Kit) was added 18 hours after transfection. Five days after transfection, 1 mL of culture was harvested, and cells were pelleted from the supernatant by centrifugation at 1,500×g for 5 minutes at 4° C. The supernatant was filtered through a 0.45 μM filter with a PVDF membrane.
[0103] The filtered supernatant containing the DS-Cav1-I53-50A construct was denatured and boiled for 10 min at 95°C in 2x Laemmli buffer containing 2-mercaptoethanol. Sample fractions were separated by SDS-PAGE, then transferred to nitrocellulose membranes and probed with palivizumab followed by anti-human secondary antibody conjugated to HRP. Blots were imaged using Clarity Western ECL blotting substrate (Bio-Rad).
[0104] The filtered supernatant containing the DS-Cav1-I53-50A construct was bound to a Nunc MaxiSorp™ 96-well plate in a two-fold dilution series. DS-Cav1-I53-50A was detected using the pre-fusion conformation specific antibody D25, followed by a secondary anti-human antibody conjugated to HRP. Protein yield was determined by colorimetry with the substrate TMB, and absorbance was collected at 450 nm.
[0105] The expression yield and binding of pre-fusion specific mAb D25 (data not shown) indicates that all constructs are fully expressed and in pre-fusion conformation. Those skilled in the art would have expected that a heterologous trimerization domain (such as foldon) would be required for proper expression and folding of pre-fusion F constructs. Our results show that the components of I53-50A nanostructures can support the expression and proper folding of DS-Cav1 without the use of trimerization domains such as foldon. The binding of D25 to these constructs suggests that the antigenicity of the constructs is intact and is expected to induce a strong immune response (including neutralizing antibodies) similar to nanostructures containing DS-Cav1-foldon-I53-50 fusion polypeptides.
[0106] This application may include the following inventions. (1) A nanostructure, (a) a plurality of first assemblies, each first assembly comprising a plurality of identical first polypeptides; (b) a plurality of second assemblies, each second assembly comprising a plurality of identical second polypeptides, the second polypeptides being different from the first polypeptide; Including, said plurality of first assemblies non-covalently interacting with said plurality of second assemblies to form a nanostructure; A nanostructure, wherein the nanostructure displays multiple copies of one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, on an exterior surface of the nanostructure. (2) (a) the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs: 1-51; (b) The nanostructure of (1), wherein the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence of a polypeptide selected from the group consisting of SEQ ID NOs: 1-51. (3) The nanostructure of (1) or (2), wherein the F protein, or antigenic fragment thereof, of one or more paramyxoviruses and / or pneumoviruses comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to a polypeptide selected from the group consisting of SEQ ID NOs: 53, 61-68, and 101. (4) The nanostructure of (1) or (2), wherein the F protein or antigenic fragment thereof of one or more paramyxoviruses and / or pneumoviruses comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to a RSV F protein or variant thereof selected from the group consisting of SEQ ID NOs: 53 and 61-64, wherein the polypeptide comprises one or more of the following residues: 67I, 149C, 458C, 46G, 465Q, 215P, 92D, and 487Q. (5) The nanostructure of any one of (1) to (2), wherein the one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof, comprise a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an MPV F protein or variant thereof selected from the group consisting of SEQ ID NOs: 65-68 and 101, wherein the polypeptide comprises one or more of the following residues: 113C, 120C, 339C, 160F, 177L, 185P, and 426C. (6) The first polypeptide and the second polypeptide are the following pair: SEQ ID NO:1 and SEQ ID NO:2 (I53-34A and I53-34B); SEQ ID NO:3 and SEQ ID NO:4 (I53-40A and I53-40B); SEQ ID NO:3 and SEQ ID NO:24 (I53-40A and I53-40B.1); SEQ ID NO:23 and SEQ ID NO:4 (I53-40A.1 and I53-40B); SEQ ID NO:35 and SEQ ID NO:36 (genera I53-40A and I53-40B); SEQ ID NO:5 and SEQ ID NO:6 (I53-47A and I53-47B); SEQ ID NO:5 and SEQ ID NO:27 (I53-47A and I53-47B.1); SEQ ID NO:5 and SEQ ID NO:28 (I53-47A and I53-47B.1NegT2); SEQ ID NO:25 and SEQ ID NO:6 (I53-47A.1 and I53-47B); SEQ ID NO:25 and SEQ ID NO:27 (I53-47A.1 and I53-47B.1); SEQ ID NO:25 and SEQ ID NO:28 (I53-47A.1 and I53-47B.1NegT2); SEQ ID NO:26 and SEQ ID NO:6 (I53-47A.1NegT2 and I53-47B); SEQ ID NO:26 and SEQ ID NO:27 (I53-47A.1NegT2 and I53-47B.1); SEQ ID NO:26 and SEQ ID NO:28 (I53-47A.1NegT2 and I53-47B.1NegT2); SEQ ID NO:37 and SEQ ID NO:38 (genera I53-47A and I53-47B); SEQ ID NO:7 and SEQ ID NO:8 (I53-50A and I53-50B); SEQ ID NO:7 and SEQ ID NO:32 (I53-50A and I53-50B.1); SEQ ID NO:7 and SEQ ID NO:33 (I53-50A and I53-50B.1NegT2); SEQ ID NO:7 and SEQ ID NO:34 (I53-50A and I53-50B.4PosT1); SEQ ID NO:29 and SEQ ID NO:8 (I53-50A.1 and I53-50B); SEQ ID NO:29 and SEQ ID NO:32 (I53-50A.1 and I53-50B.1); SEQ ID NO:29 and SEQ ID NO:33 (I53-50A.1 and I53-50B.1NegT2); SEQ ID NO:29 and SEQ ID NO:34 (I53-50A.1 and I53-50B.4PosT1); SEQ ID NO:30 and SEQ ID NO:8 (I53-50A.1NegT2 and I53-50B); SEQ ID NO:30 and SEQ ID NO:32 (I53-50A.1NegT2 and I53-50B.1); SEQ ID NO:30 and SEQ ID NO:33 (I53-50A.1NegT2 and I53-50B.1NegT2); SEQ ID NO:30 and SEQ ID NO:34 (I53-50A.1NegT2 and I53-50B.4PosT1); SEQ ID NO:31 and SEQ ID NO:8 (I53-50A.1PosT1 and I53-50B); SEQ ID NO:31 and SEQ ID NO:32 (I53-50A.1PosT1 and I53-50B.1); SEQ ID NO:31 and SEQ ID NO:33 (I53-50A.1PosT1 and I53-50B.1NegT2); SEQ ID NO:31 and SEQ ID NO:34 (I53-50A.1PosT1 and I53-50B.4PosT1); SEQ ID NO:39 and SEQ ID NO:40 (genera I53-50A and I53-50B); SEQ ID NO:9 and SEQ ID NO:10 (I53-51A and I53-51B); SEQ ID NO:11 and SEQ ID NO:12 (I52-03A and I52-03B); SEQ ID NO:13 and SEQ ID NO:14 (I52-32A and I52-32B); SEQ ID NO:15 and SEQ ID NO:16 (I52-33A and I52-33B) SEQ ID NO:17 and SEQ ID NO:18 (I32-06A and I32-06B); SEQ ID NO:19 and SEQ ID NO:20 (I32-19A and I32-19B); SEQ ID NO:21 and SEQ ID NO:22 (I32-28A and I32-28B); SEQ ID NO:23 and SEQ ID NO:24 (I53-40A.1 and I53-40B.1); SEQ ID NO:41 and SEQ ID NO:42 (T32-28A and T32-28B); SEQ ID NO:43 and SEQ ID NO:44 (T33-09A and T33-09B); SEQ ID NO:45 and SEQ ID NO:46 (T33-15A and T33-15B); SEQ ID NO:47 and SEQ ID NO:48 (T33-21A and T33-21B); SEQ ID NO:49 and SEQ ID NO:50 (T33-28A and T32-28B); and The nanostructure of any one of (1) to (5), comprising a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence selected from SEQ ID NO: 51 and SEQ ID NO: 44 (T33-31B and T33-09B (also referred to as T33-31B)). (7) The nanostructure according to any one of (1) to (6), wherein the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-31A (SEQ ID NO: 51), and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-09B / T33-31B (SEQ ID NO: 44). (8) The nanostructure according to any one of (1) to (6), wherein the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-15B (SEQ ID NO: 46), and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of T33-15A (SEQ ID NO: 45). (9) the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence selected from the group consisting of I53-50A (SEQ ID NO: 7), I53-50A.1 (SEQ ID NO: 29), I53-50A.1NegT2 (SEQ ID NO: 30), and I53-50A.1PosT1 (SEQ ID NO: 31); and the second polypeptide The nanostructure of any one of (1) to (6), comprising a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence selected from the group consisting of I53-50B (SEQ ID NO: 8), I53-50B.1 (SEQ ID NO: 32), I53-50B.1NegT2 (SEQ ID NO: 33), and I53-50B.4PosT1 (SEQ ID NO: 34). (10) The nanostructure according to any one of (1) to (6), wherein the first polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I32-28A (SEQ ID NO: 21), and the second polypeptide comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of I32-28B (SEQ ID NO: 22). (11) The nanostructure described in any one of (1) to (10), wherein the F protein, or antigenic fragment thereof, of the one or more paramyxoviruses and / or pneumoviruses is expressed as a fusion protein with the first polypeptide. (12) The nanostructure of (11), wherein each of the plurality of first assemblies comprises the same fusion protein. (13) The nanostructure described in (11), wherein the plurality of first assemblies comprises a total of two or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof. (14) The nanostructure of (11) or (12), wherein only a subset of the first polypeptides comprises a fusion protein with an F protein or an antigenic fragment thereof. (15) The nanostructure described in any one of (1) to (14), wherein each first assembly comprises a homotrimer of the first polypeptide. (16) The nanostructure of any one of (1) to (15), wherein the F protein, or antigenic fragment thereof, of the one or more paramyxoviruses and / or pneumoviruses comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to the amino acid sequence of DS-Cav1 (SEQ ID NO: 53). (17) The nanostructure described in any one of (11) to (16), wherein each fusion protein comprises an amino acid linker disposed between the first polypeptide and the one or more paramyxovirus and / or pneumovirus F proteins, or antigenic fragments thereof. (18) The nanostructure of (17), wherein the amino acid linker sequence comprises one or more trimerization domains. (19) The nanostructure of (17) or (18), wherein the amino acid linker sequence comprises the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO: 54). (20) The nanostructure of (17), wherein the amino acid linker sequence comprises a Gly-Ser linker. (twenty one) The nanostructure according to any one of (11) to (20), wherein the fusion protein comprises a polypeptide having at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity along its entire length to an amino acid sequence selected from the group consisting of SEQ ID NOs: 69 to 100. (twenty two) (a) when each fusion protein is DS-Cav1-foldon-T33-31A (SEQ ID NO: 69) or DS-Cav1-T33-31A (SEQ ID NO: 70), each second polypeptide is T33-31B (SEQ ID NO: 44); (b) when each fusion protein is DS-Cav1-foldon-T33-15B (SEQ ID NO: 71) or DS-Cav1-T33-15B (SEQ ID NO: 72), each second polypeptide is T33-15A (SEQ ID NO: 45); (c) when each fusion protein is DS-Cav1-foldon-I53-50A (SEQ ID NO: 73) or DS-Cav1-I53-50A (SEQ ID NO: 74), each second polypeptide is I53-50B (SEQ ID NO: 8), I53-50B.1 (SEQ ID NO: 32), I53-50B.1NegT2 (SEQ ID NO: 33), or I53-50B.4PosT1 (SEQ ID NO: 34); or (d) When each fusion protein is DS-Cav1-I32-28A (SEQ ID NO: 75), each second polypeptide is I32-28B (SEQ ID NO: 22). The nanostructure of (21), (twenty three) The nanostructure of (16), wherein each first polypeptide comprises a fusion protein of DS-Cav1 (SEQ ID NO: 53) linked to SEQ ID NO: 7 (I53-50A) via an amino acid linker. (twenty four) The nanostructure of (23), wherein the amino acid linker comprises a Gly-Ser linker and / or a helix extension domain. (twenty five) The nanostructure according to any one of (11) to (24), wherein each fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 69 to 77 and 81 to 90. (26) The nanostructure according to any one of (23) to (24), wherein each fusion protein comprises the amino acid sequence of SEQ ID NO: 76 (F10). (27) The nanostructure according to any one of (23) to (25), wherein each second polypeptide comprises an amino acid sequence selected from the group consisting of I53-50B (sequence number 8), I53-50B.1 (sequence number 32), I53-50B.1NegT2 (sequence number 33), or I53-50B.4PosT1 (sequence number 34). (28) The nanostructure according to any one of (23) to (27), wherein each second polypeptide comprises the amino acid sequence of I53-50B.4PosT1 (SEQ ID NO: 34). (29) The nanostructure comprises: (a) binds to a pre-fusion F-specific antibody (including but not limited to monoclonal antibody D25); (b) forming a symmetrical structure (including, but not limited to, an icosahedral structure); (c) is stable at 50°C; and / or (d) The nanostructure according to any one of (1) to (28), which is stable in 2.25 M guanidine hydrochloride. (30) A recombinant nucleic acid encoding a first polypeptide fusion protein according to any one of (11) to (29). (31) A recombinant expression vector comprising the recombinant nucleic acid according to (30) operably linked to a promoter. (32) A recombinant host cell comprising the recombinant expression vector according to (31). (33) A recombinant host cell comprising one or more recombinant expression vectors capable of expressing the first polypeptide and the second polypeptide according to any one of (1) to (29). (34) An immunogenic composition comprising the nanostructure according to any one of (1) to (29) above, and a pharma- ceutically acceptable carrier. (35) The immunogenic composition according to (34), further comprising an adjuvant. (36) A method for generating an immune response in a subject against an F protein of a paramyxovirus and / or a pneumovirus, comprising the step of administering to the subject in need thereof an effective amount of a nanostructure or immunogenic composition described in any one of (1) to (29) and (34) to (35) to generate an immune response. (37) A method for treating or limiting a paramyxovirus and / or pneumovirus infection in a subject, comprising administering to the subject in need thereof an effective amount of a nanostructure or immunogenic composition described in any one of (1) to (29) and (34) to (35), thereby treating or preventing a paramyxovirus and / or pneumovirus infection in the subject. (38) The method according to (36) or (37), wherein the administration produces neutralizing antibodies to paramyxovirus and / or pneumovirus in the subject. (39) The neutralizing antibody has a titer of at least 1,000 (1 / ID 50 ) is present in the serum of the subject. (40) A process for assembling a nanostructure according to any one of claims (1) to (29) in vitro, comprising mixing two or more nanostructure components in aqueous conditions to drive spontaneous assembly of the desired nanostructure. (41) The process of (40), wherein the mixing step comprises mixing a first assembly comprising first polypeptides (such as trimeric first polypeptides), each comprising an F protein or an antigenic fragment thereof ("F protein"), with a suitable second assembly comprising a second polypeptide, in a molar ratio of first polypeptide:second polypeptide of approximately 1:1, under suitable conditions and for a time for the first assembly and the second assembly to interact to form the nanostructure. (42) The process of (40), wherein the mixing step comprises mixing a first assembly comprising a first polypeptide (such as a trimeric first polypeptide) in which less than all of the first polypeptides (e.g., 75%, 50%, 25%, etc.) comprise an F protein with a suitable second assembly comprising a second polypeptide in a molar ratio of first polypeptide:second polypeptide of approximately 1:1 under suitable conditions and for a time period for the first assembly and the second assembly to interact to form the nanostructure. (43) The process of (40), wherein the mixing step comprises mixing a first assembly comprising first polypeptides (such as a trimeric first polypeptide), each comprising an F protein, the first polypeptides comprising a plurality of different F proteins (e.g., 2, 3, 4, or more) across the first polypeptides, with a suitable second assembly comprising a second polypeptide, in a molar ratio of first polypeptide:second polypeptide of approximately 1:1, under suitable conditions and for a time for the first assembly and the second assembly to interact to form the nanostructure comprising a plurality of F proteins or antigenic fragments thereof.
Claims
[Claim 1] 20. A nanostructure, composition or method substantially as described herein.
